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Literature review  
Note – this abstract is longer than standard, to meet PRISMA guidelines required by 
the journal (BMJ).  
Anxiety and depression are thought to be common in Chronic Fatigue Syndrome, 
although the reported prevalence of these difficulties varies between studies. These 
comorbidities are known to have implications for patient wellbeing and health, and 
there is some evidence that they might have implications for outcomes to treatment 
for Chronic Fatigue. The current review aimed to examine the prevalence of anxiety 
and depression, and to investigate whether these difficulties affect fatigue and 
physical function outcomes in available randomised controlled trials of NICE 
endorsed evidence-based treatment.  
A systematic review, meta-analysis and meta-regression were completed. Published 
and unpublished (a) randomised controlled trials of (b) CBT or GET for (c) adults 
with (d) CFS, in which (e) post-intervention fatigue and/or physical function scores 
were reported, and (f) anxiety and/or depression scores were reported at baseline, were 
identified, from searches of three databases (Pubmed, Embase, PsycINFO) and 
reference lists of included studies and relevant reviews. Searches took place on 10th 
April 2017. Risk of bias was assessed using the Cochrane Risk of Bias tool. Estimates 
of depression and anxiety were summarised with a narrative review. Meta-regression 
models were used to explore whether anxiety and depression are associated with 
outcomes to treatment. 
Nine papers were identified and included in the review. The analysis indicated that 
reported rates of anxiety and depression were heterogeneous between studies, but that 
up to 55% of participants experience comorbid depressive disorders, with 10-20% 
experiencing major depressive disorder, and that 10-48% of participants experience a 
comorbid anxiety disorder. Meta-regressions indicated that depressive symptoms 
were associated with less improvement in physical function following treatment (nine 
studies). Depression was not associated with fatigue outcomes; anxiety was not 
associated with either fatigue or physical function outcomes. 
The findings have important implications for the support and treatment of patients 
with Chronic Fatigue Syndrome. For patients to receive the best possible care, it is 
imperative that clinicians and services address all presenting physical and 
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psychological needs, to optimise treatment outcomes. Patients experiencing comorbid 
depression may benefit from essential interventions aimed at addressing depressive 
symptoms before or alongside treatment for Chronic Fatigue to increase treatment 
response.  
Service Improvement Project 
Mind-maps are a graphical communication technique that has been found to enhance 
therapeutic work in substance misuse services. Despite their value in these settings, 
they have not been so frequently utilised in general mental health provision. To 
address this gap, a mind-map booklet, the “My Wellbeing Toolkit” was recently 
developed and introduced in an NHS Recovery Service. The current service 
improvement project aimed to explore uptake of the booklet and make 
recommendations for improvements to the booklet. 
A three-stage sequential explanatory mixed methods study was used to explore the 
evaluation questions: the initial stage involved collecting data on the number of care 
coordinators who had used the booklet, from existing logs, the second stage involved 
collection of questionnaire data on usage patterns of the booklet, the third involved 
collection of qualitative data on experiences of using the booklet. Quantitative data 
was explored using descriptive statistics; qualitative data was analysed using thematic 
analysis. 
Care coordinators identified that the booklet was useful for themselves and for clients, 
however uptake of the booklet was low. A number of barriers were identified: 
practical barriers, lack of confidence and clarity when using the booklet and a lack of 
client engagement. A series of recommendations were made to address these barriers 
and to improve the content of the booklet. 
The project suggests that mind-map booklets have considerable value for mental 
health provision, however support needs to be provided to clinicians to facilitate their 
use. Future directions for research include exploring client experiences of mind-map 
based booklets. 
Main Research Project 
Cervical cancer patients are at particular risk of experiencing psychological distress 
and mental health difficulties. The current study investigated whether this is 
x 
associated with knowledge of the sexually-transmitted nature of HPV, exploring 
HPV-related shame, anxiety and low mood in women with cervical cancer.  
110 women with cervical cancer completed a repeated measures study, during which 
they read information that HPV is (1) considered to be a sexually-transmitted virus 
and (2) very common. Participants completed measures of shame, mood and anxiety 
after each level of information.  
The results indicated that information that HPV is sexually-transmitted is associated 
with experiences of shame. Increased shame was associated with depression, low 
mood, anxiety and poor wellbeing. Women with a history of depression and anxiety 
were at particular risk for experiencing high levels of shame.  
The results indicate that women with cervical cancer experience high levels of shame 
related to HPV information. This has implications for how to support patients who are 
at risk of experiencing high levels of shame, particularly around HPV-information 
provision, identifying at-risk patients, and the psychological support of patients. 
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Anxiety and depression are thought to be common in Chronic Fatigue Syndrome, 
although the reported prevalence of these difficulties varies between studies. These 
comorbidities are known to have implications for patient wellbeing and health, and 
there is some evidence that they might have implications for outcomes to treatment 
for Chronic Fatigue. The current review aimed to examine the prevalence of anxiety 
and depression, and to investigate whether these difficulties affect fatigue and 
physical function outcomes in available randomised controlled trials of NICE 
endorsed evidence-based treatment.  
A systematic review, meta-analysis and meta-regression were completed. Published 
and unpublished (a) randomised controlled trials of (b) CBT or GET for (c) adults 
with (d) CFS, in which (e) post-intervention fatigue and/or physical function scores 
were reported, and (f) anxiety and/or depression scores were reported at baseline, were 
identified, from searches of three databases (Pubmed, Embase, PsycINFO) and 
reference lists of included studies and relevant reviews. Searches took place on 10th 
April 2017. Risk of bias was assessed using the Cochrane Risk of Bias tool. Estimates 
of depression and anxiety were summarised with a narrative review. Meta-regression 
models were used to explore whether anxiety and depression are associated with 
outcomes to treatment. 
Nine papers were identified and included in the review. The analysis indicated that 
reported rates of anxiety and depression were heterogeneous between studies, but that 
up to 55% of participants experience comorbid depressive disorders, with 10-20% 
experiencing major depressive disorder, and that 10-48% of participants experience a 
comorbid anxiety disorder. Meta-regressions indicated that depressive symptoms 
were associated with less improvement in physical function following treatment (nine 
studies). Depression was not associated with fatigue outcomes; anxiety was not 
associated with either fatigue or physical function outcomes. 
The findings have important implications for the support and treatment of patients 
with Chronic Fatigue Syndrome. For patients to receive the best possible care, it is 
imperative that clinicians and services address all presenting physical and 
psychological needs, to optimise treatment outcomes. Patients experiencing comorbid 
depression may benefit from essential interventions aimed at addressing depressive 
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symptoms before or alongside treatment for Chronic Fatigue to increase treatment 
response.  
Key words 





Chronic Fatigue Syndrome, also referred to as Myalgic Encephalomyelitis (CFS), is 
a severely disabling condition affecting 0.2%-2% of the general adult UK population. 
The condition is characterised by extreme fatigue and a range of other symptoms 
including cognitive impairment, pain and sleep difficulties (Nacul et al., 2011). As 
there is currently no universal agreement on the underpinning pathogenesis of the 
condition (NICE, 2007), present treatment focuses on management of symptoms and 
living well with CFS, with NICE guidelines recommending cognitive behavioural 
therapy (CBT), graded exercise therapy (GET) and activity management programmes 
as best care (NICE, 2007). However, response rates to these treatments are limited, 
with small to medium effect sizes at best (Castell, Kazantzis, & Moss‐Morris, 2011; 
Larun, Brurberg, Odgaard-Jensen, & Price, 2015; Price, Mitchell, Tidy, & Hunot, 
2008), with a number of patients reporting little or no improvement following 
treatment, and even worsening of symptoms (White et al., 2011). 
Considering these unimpressive outcomes and the variable prognosis patients face, it 
is important to examine factors associated with both the quality of life of patients 
living with CFS and treatment outcomes, in order to optimise patient wellbeing and 
improve clinical outcomes. One factor that may have importance is comorbidity of 
anxiety and depression. Research suggests that comorbid anxiety and depression are 
common in CFS, above rates observed in the general population, with a recent small-
scale study finding rates of anxiety and depression in CFS at 42.2% and 33.3% 
respectively (Daniels, Brigden, & Kacorova, 2017). However, estimates vary 
considerably and it is difficult to infer true prevalence (Kacorova, 2013). For example, 
studies report estimates of major depression ranging from 5.6% (Taylor & Jason, 
1998) to 50% (Axe, Satz, Rasgon, & Fawzy, 2004), and estimates of anxiety ranging 
from ⁓20% (e.g. Farmer et al., 1995; Pepper, Krupp, Friedberg, Doscher, & Coyle, 
1993) to ⁓52% (e.g. Millon et al., 1989; Wessely, Chalder, Hirsch, Wallace, & Wright, 
1996). This problem has been contributed to by the varying diagnostic criteria and 
measurement of comorbidities applied in studies, nevertheless variability cannot 
entirely be attributed to measurement heterogeneity, with differences observed even 
when the same diagnostic criteria and measurement are applied (e.g. Cella, White, 
Sharpe, & Chalder, 2013; Nater et al., 2009). 
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Anxiety and depression are known to pose a particular risk for increased disability 
and symptomology,  poor adjustment to illness and reduced quality of life in CFS (e.g. 
Cella, Sharpe, & Chalder, 2011; Cella et al., 2013; Moss-Morris, Sharon, Tobin, & 
Baldi, 2005). Indeed, in other long-term health conditions these comorbidities have 
been found to have a greater impact on the functional status and quality of life of 
patients than the level of severity of their physical illness (Eisner et al., 2010; Johnson, 
Jones, Seidenberg, & Hermann, 2004; Naylor et al., 2012). Research has suggested 
that the impact of anxiety and depression on wellbeing and disability in CFS may be 
associated with specific patterns of cognition and behaviour. In particular, anxiety has 
been found to be associated with beliefs about damage from CFS and hypervigilance 
and depression has been found to be associated with avoidance, hypervigilance to 
symptoms and catastrophising (Cella et al., 2013). While these thinking styles and 
behaviours are understandable in the context of a distressing and disabling condition 
which is so poorly understood, it is evident that, if we are to improve patient 
wellbeing, we need to fully understand the prevalence and impact of these 
comorbidities. 
Beyond immediate quality of life, evidence suggests that these comorbidities likely 
also impact on treatment outcomes and prognosis (e.g. Flo & Chalder, 2014). There 
is emerging evidence that depressive symptoms may be associated with poorer 
outcomes to CBT (Flo & Chalder, 2014) and psychoeducation programs aimed at 
encouraging graded exercise (Bentall, Powell, Nye, & Edwards, 2002), suggesting 
depression might impact treatment engagement, adherence and response, similarly to 
other health conditions (DiMatteo, Lepper, & Croghan, 2000). There is currently a 
lack of research into whether anxiety symptoms are related to CFS treatment 
outcomes, with the only available paper failing to find a relationship (Flo & Chalder, 
2014). However, a meta-analysis exploring other health conditions, found a variable 
impact of anxiety on treatment adherence (DiMatteo et al., 2000), suggesting that this 
relationship may be complex and require further research. 
The above research suggests that comorbid anxiety and depression are likely common 
in CFS, with significant impact on the wellbeing and functional status of patients. 
Furthermore, there is emerging evidence that these comorbidities may impact on 
treatment outcome and prognosis, which is particularly important given the 
unimpressive outcomes to current recommended treatments for the condition. 
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However, the available literature is hampered by the heterogeneity of reported 
prevalence, and the limited research on the impact of these comorbidities on 
outcomes, particularly concerning anxiety. Furthermore, research has not established 
which outcomes these comorbidities may affect. Therefore, further data on the 
prevalence and influence of anxiety and depression on outcomes in CFS is needed to 
contribute to both clinical knowledge and treatment targets and to help clinicians to 
adapt and prioritise treatment accordingly. 
Therefore, the current systematic review and meta-analysis has two aims. First, it aims 
to provide an accurate understanding of the prevalence of anxiety and depressive 
disorders in CFS. Secondly, it aims to examine whether anxiety and depression 
moderate the effectiveness of the current recommended treatments, CBT and GET, 
and explore whether this effect is specific to certain outcomes. The review aims to 
explore these questions by identifying published and unpublished randomised 
controlled trials of CBT or GET for adults with CFS, in which post-intervention 
fatigue and/or physical function scores are reported and anxiety and/or depression 
scores are reported at baseline.  
It is intended that the review will provide an accurate understanding of the prevalence 
of these difficulties and how they might affect the effectiveness of treatment. This 
knowledge will inform best care and practice and ensure that patients’ psychological 
needs are not left unmet.  
Method 
The study was registered on PROSPERO (ID CRD42016039813).  
Search strategy 
Published and unpublished trials were identified through systematic searches of 
Pubmed, Embase and PsycINFO, completed on 10th April 2017. Searches combined 
terms indicative of CFS, CBT and GET and randomised controlled trials, with UK 
and US spellings. Search terms identifying randomised controlled trials were tailored 
to each database following guidelines in the Cochrane handbook (2011): Embase 
(Lefebvre et al., 2011), Pubmed (sensitivity- and precision-maximizing version (2008 
revision); Lefebvre et al., 2011), PsycINFO (Eady, Wilczynski, & Haynes, 2008). For 
full search terms, see Appendix B. 
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There were no additional limits placed on searches. The reference and citation lists of 
randomised controlled trials, systematic reviews and meta-analyses were also checked 
for additional trials. 
Selection criteria 
Published and unpublished (a) randomised controlled trials of (b) CBT or GET for (c) 
adults with (d) CFS, in which (e) post-intervention fatigue and/or physical function 
scores were reported, and (f) anxiety and/or depression scores were reported at 
baseline, were identified for possible inclusion in the review.  
Details of PICO eligibility criteria are described below, as are details of requirements 
placed on studies for measuring baseline/moderator variables of depression and 
anxiety. 
Selection criteria were adapted from Kacorova (2013). 
 Population/patient characteristics and setting. Trials of male and female 
participants over the age of 18 were included; trials of children and adolescents were 
not eligible for inclusion, as it has been suggested that they may represent a different 
pathology (Collin, Nuevo, van de Putte, Nijhof, & Crawley, 2015). Studies were 
included regardless of culture and setting, although papers had to be written in 
English. CFS was required to be assessed using the Centers for Disease Control 
(CDC) criteria, referred to as the Fukuda criteria (Fukuda et al., 1994) or the Oxford 
criteria (Sharpe et al., 1991), as the two primary criteria used in research; trials using 
equivalent criteria were also included. Studies including participants with physical 
health comorbidities that could account for CFS symptomology were excluded, in line 
with diagnostic criteria (Fukuda et al., 1994; Sharpe et al., 1991) and to prevent 
inclusion of  participants who had been incorrectly diagnoses with CFS. Studies 
including participants with comorbid mental health diagnoses were included, 
providing the diagnosis was deemed secondary to CFS. 
Intervention characteristics. Randomised controlled trials of CBT and GET 
in which a CFS-specific intervention was clearly described were included. Studies 
that did not apply a CFS-specific protocol were excluded, for example stress-
management interventions. There were no restrictions on the length or duration of 
treatment, or the format of treatment, for example both individual and group-based 
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treatments were eligible for inclusion. For the purposes of the review, CBT or GET 
in combination with other interventions were not included, as the evidence base for 
these interventions is more limited (NICE, 2007).  
Comparison/control characteristics. Studies were required to have a control 
group, which could include: (1) Standard medical management and care, including 
treatment as usual or waiting list (2) Pharmacological therapy (3) Non-CBT or GET 
psychological therapies, including relaxation or non-directive therapies; these 
psychological therapies were included as they contain none of the active components 
of treatment associated with CBT and GET. 
If a study included multiple control groups, the condition that appeared to control best 
for therapist attention (Kendal, Holmbeck, & Verduin, 2004) was chosen as the 
comparison group. 
 Outcome measures. The principle outcome used in this review was fatigue, 
measured either as (1)  Change in fatigue severity (continuous) as indexed by the 
Chalder Fatigue Scale (Chalder et al., 1993), or any other validated, or clearly 
described, fatigue scale, or (2) Clinical recovery or change (dichotomous), based on 
defined cut-off on validated scales. 
The secondary outcome was improvement in overall patient- or clinician-rated 
physical functioning. 
Baseline/moderator variables. To be included in the review, depression 
and/or anxiety had to be assessed and reported at baseline using a recognised and 
validated measure or diagnostic criteria. Anxiety and depression diagnoses eligible 
for inclusion were decided through consultation with an expert in the field (JD), and 
consulting DSM-3, DSM-IV and ICD-10. General measures of wellbeing or distress 
were excluded. 
Other considerations. If publications containing secondary analyses of 
previously-published data were identified, the primary report of the study was used. 
Secondary analyses were disregarded, unless the report provided additional data not 
available in the original publication.  
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Data extraction and quality assessment  
Following database searches, titles and abstracts of articles were retrieved and 
transferred to Covidence for assessment. Two investigators (AC and HW; 100% and 
20% respectively) then checked abstracts against the above described eligibility 
criteria. Titles and abstracts which did not provide sufficient detail to check all 
inclusion criteria were met, but did not meet any exclusion criteria, were included for 
full review. Disagreements were resolved through discussion with JD, a senior 
investigator and expert in the field; see Appendix D. Full texts of potentially relevant 
articles were then screened (AC and HW, 100% and 20% respectively), using a 
standardised form; borderline papers were again discussed and resolved with JD. Data 
extraction was completed by AC, using the extraction form, before meta-analysis. 
When papers were ambiguous, or data were insufficient, authors were contacted. 
Authors were requested to provide additional data if a study met all requirements other 
than reporting anxiety or depression data at baseline; if an author was unable to 
provide said data, the study was not included within the analysis. Authors were also 
contacted to clarify the lower age limit of participants, if unclear; if authors did not 
respond, the paper was included, unless the paper referenced the inclusion of 
adolescents or children. Finally, leading authors in the field were contacted to provide 
any unpublished data. For a full list of contacted authors, see Appendix C. 
Several aspects of the included studies were assessed and recorded, including study 
characteristics, such as number of participants randomised to the study, total number 
of treatment arms (although all treatment arms were not necessarily included in the 
analysis) and country. Participant characteristics were also recorded, including CFS 
diagnostic criteria, lower age range of participants and the number of female 
participants. Aspects of treatment, including whether the study applied a CBT or GET 
intervention, whether the intervention was individual or group-based and number of 
sessions, were recorded, as was the type of control group. Finally, Fatigue and 
Physical function outcome measures were recorded, as were measures of anxiety and 
depression at baseline (see Appendix E for extraction form). 
Risk of bias in individual studies was assessed with the Cochrane risk of bias 
assessment tool, by AC and HW (resolved through agreement), which assesses seven 
domains of (1) random sequence generation (2) allocation concealment (3) blinding 
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of participants and personnel (4) blinding of outcome assessment (5) incomplete 
outcome data (6) selective reporting, and if there was evidence of (7) other bias. This 
information was summarised during data synthesis.  
Data synthesis  
Characteristics and results of all included studies were tabulated, including baseline 
rates of depression and anxiety, mean scores on measures of depression and anxiety, 
and post-intervention scores on measures of fatigue and physical functioning.  
Selection and inclusion of studies. Numbers of retrieved and included studies 
were detailed. Inter-rater reliability for abstract screens and full texts was formally 
assessed using Gwet’s AC1 statistic, calculated using AgreeStat version 2015.6.1 
(Advanced Analytics LLC, Gaithersburg, MD, USA). Gwet’s AC1 was preferred to 
the more widely-used Cohen’s Kappa, as Kappa is sensitive to imbalances in trait 
prevalence in the subject population and can produce low estimates of chance-
corrected agreement even when absolute agreement is high (Feinstein & Cicchetti, 
1990; Gwet, 2002). 
Study characteristics. Study characteristics were summarised using a 
narrative synthesis, presenting relevant details of included studies.  
Prevalence of comorbid depression and anxiety in CFS sample. A 
narrative synthesis was used to explore the prevalence of depression and anxiety. 
Rates of anxiety and depression were identified, according to the number/percentage 
of participants meeting clinical cut-offs, according to validated measures, and/or 
diagnostic criteria within each paper.  
Mean scores on measures of depression/anxiety within each paper were then 
summarised. If papers reported mean scores within groups, but not within the whole 
sample, sample means and SDs were calculated using available group means and SDs. 
It was also recorded whether papers made exclusions based on depression and anxiety.  
Effects of anxiety and depression on treatment outcomes: meta-analyses 
and meta-regression. While the focus of the current paper was not to complete a 
meta-analysis exploring the effectiveness of CBT and GET for CFS, (as this has been 
done before, (e.g. Castell et al., 2011; Larun et al., 2015; Price et al., 2008), initial 
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meta-analyses were performed to identify potential variability in effect sizes among 
the identified papers. Two random-effects meta-analyses were performed, using the 
inverse variance method to pool the effect sizes across studies. Random effects models 
were used as it is assumed differences in methods and sample characteristics among 
the sample studies result in heterogeneity in the true effects sizes. The first explored 
the effectiveness of psychotherapy on fatigue outcomes, and the second explored the 
effectiveness on physical function outcomes. Again, CBT and GET interventions 
were grouped, as there was not sufficient power to assess the interventions in separate 
models. For each meta-analysis, t2 was calculated using the DerSimonian-Laird 
estimator, and the I2 statistic, with 95% confidence intervals, and Q-statistic were used 
to assess heterogeneity in the effect sizes. I2 values of around 25%, 50%, and 75% 
represent low, medium, and large values of heterogeneity, respectively (Higgins & 
Thompson, 2002). Funnel plots were examined for asymmetry in effect sizes (Sterne 
et al., 2011). 
Four mixed-effect meta-regression models were then estimated to explore whether 
anxiety and depression could account for heterogeneity in effect sizes for fatigue and 
physical function outcomes. In each model anxiety or depression was included as the 
predictor variable, with fatigue or physical functioning as the outcome variable. As 
anxiety and depression had been reported on different scales for some studies, data 
were rescaled to standardise the date to the same metric. Given the small sample sizes, 
separate regressions were performed for anxiety and depression to preserve degrees 
of freedom and maximise power. Two papers were missing anxiety data at baseline, 
therefore including both depression and anxiety within one model would have resulted 
in significant loss of power for the depression variable.  
Meta-analyses and meta-regressions were performed using the metafor package in R 
3.4.3. 
Calculation of effect sizes. All outcomes, except for fatigue outcomes 
reported in Wearden et al., (1998) were continuous, therefore standardised mean 
differences (Cohen’s d) were calculated as the effect size. Effect sizes of 0.8 are 
considered large, while effect sizes of 0.5 are moderate, and effect sizes of 0.2 are 
considered small (Cohen, 1988). When multiple follow-up scores were reported, the 
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scores immediately post-intervention, or those closest to the end of the intervention 
were used. 
For fatigue outcomes reported in Wearden et al. (1998) an odds ratio was calculated 
using the number of non-cases (no fatigue) post-treatment, which was then converted 
to a standardised mean difference.  
White et al. (2011) contained independent CBT and GET treatment arms, therefore 
separate effect sizes of the effectiveness of CBT and GET were calculated; White et 
al. (2011) is consequently represented twice in each meta-analysis and regression. 
Sharpe et al (1996) did not report standard deviations corresponding to post treatment 
and control means, and the author was unable to provide the data when contacted by 
email; effect sizes were therefore calculated using data provided in a published 
Cochrane review (Price et al., 2008). 
Results 
Selection and inclusion of studies 
The systematic searches identified 1042 unique records. Of these 146 full texts were 
retrieved and read. 15 borderline papers were resolved and excluded through 
discussion: five papers were excluded for reporting general measure of psychological 
wellbeing/distress, but not a specific measure of anxiety/depression (Lopez et al., 
2011; Prins et al., 2001; Tummers, Knoop, van Dam, & Bleijenberg, 2013; Vos-
Vromans et al., 2016; Wiborg, van Bussel, van Dijk, Bleijenberg, & Knoop, 2015); 
seven were excluded for using a partial CBT intervention or combination treatment 
(Friedberg, Adamowicz, Caikauskaite, Seva, & Napoli, 2016; Nunez et al., 2011; 
Rimes & Wingrove, 2013; Surawy, Roberts, & Silver, 2005; Thomas, Sadlier, & 
Smith, 2006; Thomas, Sadlier, & Smith, 2008; Wearden et al., 2010); two were 
excluded for not including a suitable control condition (Burgess, Andiappan, & 
Chalder, 2012; Windthorst et al., 2017); one paper was excluded as the study had not 
excluded patients with relevant physical health comorbidities (Strang, 2002). 
Nine studies were found to the meet criteria and are included in the review. See Figure 
1 for Prisma flow diagram. 
Absolute agreement among screeners was high at the abstract stage (93.6%), with a 
Gwet’s AC1 value of 0.918 (95% CI 0.874, 0.962). Absolute agreement among 
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screeners was also high at the full text stage (82.7%), with a Gwet’s AC1 value of 


















Figure 1. PRISMA flowchart showing study selection process 
Characteristics of included studies 
Characteristics of included studies (Barrett, 1992; Deale, Chalder, Marks, & Wessely, 
1997; Fulcher & White, 1997; Jason et al., 2007; Moss-Morris et al., 2005; O'Dowd, 
Gladwell, Rogers, Hollinghurst, & Gregory, 2006; Sharpe et al., 1996; Wearden et al., 
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1998; White et al., 2011) are shown in Table 1. The size of the studies varied from 
between 43 and 641 participants. Five studies applied a CBT intervention, three used 
GET, and one study (White et al., 2011) included both CBT and GET in two separate 
treatment arms.  
Quality of included studies varied (see Figure 2), but several studies gave insufficient 
















Figure 2. Figure showing quality of included studies 



























































































































































































































































































































































































































































































































































































































































































































































































































































Participant information was inconsistently presented between studies.  Age and 
gender are reported in Table 1. Seven papers reported work/employment status of 
participants (Barrett, 1992; Deale et al., 1997; Fulcher & White, 1997; Jason et al., 
2007; Moss-Morris et al., 2005; Sharpe et al., 1996; Wearden et al., 1998); samples 
included ranged from 24.6-60% of participants being on disability benefits; 22.4-70% 
of participants were unemployed. 
Three papers (Moss-Morris et al., 2005; Wearden et al., 1998; White et al., 2011) 
reported the median duration of illness of their full sample, which ranged from a 
median of 28-37 months. One paper (Barrett, 1992) reported participants had a mean 
duration of 98 months; one paper (O'Dowd et al., 2006) specified that 49% of 
participants had experienced symptoms for “more than 5 years”. 
Prevalence of comorbid depression and anxiety in CFS sample 
Eight papers reported that they had excluded participants with concurrent severe 
depression and/or anxiety from participating in their study; see Table 2 for details.  
With regards to the prevalence of depression and anxiety according to diagnostic 
criteria or clinical cut-offs, seven of the nine papers reported the prevalence of clinical 
depression in their sample. While measurement of depression varied, rates ranged 
from 10-20% of patients meeting criteria for major depression, and 8-55% met criteria 
for “any depressive disorder”. Six of the nine papers reported the prevalence of 
clinical anxiety within their sample. While measurement of anxiety also varied, rates 
ranged from 10-48% of patients meeting criteria for “any anxiety disorder” (see Table 



















































































































































































































































































With regards to baseline scores on measures of depression and anxiety, all nine papers 
reported baseline scores on a questionnaire measure of depression; 8 papers reported 
means, one reported median scores. These ranged from 14.35-18.66 on the BDI, and 
6.19-8.77 on the HADS. See Table 3 for details. Seven of the nine papers reported 
baseline scores on a questionnaire measure of anxiety; 6 papers reported means, one 
reported median scores. These ranged from 6.94-8.39 on the HADS. See Table 3 for 
details.  
Table 3. Table showing mean depression and anxiety scores reported in included 
studies   
*Median reported as means not available. 
BDI-I = Beck Depression Inventory, version I; HADS = Hospital Anxiety and 
Depression Scale; BDI-II = Beck Depression Inventory, version II; A-State scale = 
Anxiety State Scale; BAI = Beck Anxiety Inventory 
 
Effects of anxiety and depression on treatment outcomes: meta-analyses and 
meta-regression 
The effects of CBT and GET on fatigue were compared with a control group in nine 
studies, with ten comparisons [as White et al (2011) included both CBT and GET 
comparisons]. Psychotherapy was found to reduce fatigue [SMD = 0.423, p<.001 
(95% CI 0.274, 0.572)], see Figure 3. Between study heterogeneity was low [I2 = 
17.8% (0.0%, 58.8%)] and the Q test was not statistically significant, 2 (9) = 10.94, 
p = .280. However, Huedo-Medina et al. (2006) note that the Q test is underpowered 
when fewer than 20 studies are included in the meta-analysis.  
 Depression Anxiety 
Paper Assessment 
instrument 
Mean score Assessment 
instrument 
Prevalence 
Barrett 1992 BDI-I 14.46 (7.85) A-State scale 43.78(13.92) 
Deale 1997 BDI-I 14.35 (6.65) - - 
Fulcher 1997 HADS 5* HADS 4.75* 
Jason 2007 BDI-II 18.66 (9.74) BAI 12.58 (7.90) 
Moss-Morris 2005 HADS 6.19 (1.70) HADS 6.94 (3.44) 
O'Dowd 2006 HADS 8.70 (3.52) HADS 10.29 (4.18) 
Sharpe 1996 HADS 6.75 (3.6) HADS 7.35 (4.25) 
Wearden 1998 HADS 8.77 (3.50) - - 
White 2011 HADS 8.15 (3.78) HADS 8.02 (4.25) 
      19 
Inspection of the funnel plot (Figure 4) indicated some asymmetry. 
 












Figure 4. Funnel plot of standardised mean differences and standard error for fatigue 
outcomes 
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The effects of CBT and GET on physical functioning were compared with a control 
group in 8 studies. Psychotherapy was found to improve physical functioning [SMD 
0.347, p<.001 (95% CI 0.174, 0.520)], see Figure 5. Heterogeneity was low [I2 = 
30.7% (0.0%, 69.1%)] and the Q test was not significant, 2 (7) = 10.10, p = .183. 
Inspection of the funnel plot (Figure 6) indicated some asymmetry. 













Figure 6. Funnel plot of standardised mean differences and standard error for fatigue 
outcomes  
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Meta-regression 
Depression severity was associated with less improvement in physical functioning to 
therapy: studies reporting higher baseline depression scores reported lower effect 
sizes of treatment, B = -0.112, p = .030, (95% CI -0.214, -0.011). The pseudo R2 value 
indicated that depression severity explained all the variance in the effect sizes; 
however, there is evidence that pseudo R2 is unreliable when the number of studies is 
small (Lopez-Lopez, Marin-Martinez, Sanchez-Meca, Van den Noortgate, & 
Viechtbauer, 2014). 
Depression was not associated with changes in fatigue and anxiety scores were not 
associated with any change in fatigue or physical functioning, see Table 4. 
 
Table 4. Table showing B, SE B, 95% CIs and p values for the four regression models. 
 
Discussion 
The current review set out to provide an accurate understanding of the prevalence of 
anxiety and depressive disorders in Chronic Fatigue Syndrome, and to explore 
whether these comorbidities affect treatment outcomes for CFS, with an aim to 
contribute to both clinical knowledge and treatment targets and help clinicians to 
adapt and prioritise treatment accordingly. These aims were addressed through a 
systematic review, meta-analysis and meta-regressions. The results indicated that 
comorbid anxiety and depression are common in CFS, and, importantly, that severity 
of depressive symptoms is significantly associated with poorer improvement in 
physical functioning following treatment. There was no association between anxiety 
and treatment outcomes, nor an association between depression and fatigue outcomes.  
 Fatigue Physical function 
Moderator B SE p 95% CI B SE p 95% CI 
Depression -0.03 0.05 .55 [-.13, .07] -0.11 0.05 .03 [-.21, -.01] 
Anxiety -0.04 0.05 .44 [-.13, .06] -0.02 0.05 .66 [-.11,.07] 
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The included studies indicated that up to 55% of participants experienced comorbid 
depressive disorders, with 10-20% experiencing major depressive disorder. As all but 
one study made exclusions based on depressive and other disorders, it is likely that 
these estimates may even be conservative, and the true prevalence may be 
considerably higher. The values reported, suggest that rates of major depression 
appear to be two- to eight-fold those observed in the general population (estimates 
suggest 1-week prevalence rates of 2.3%, and that 4% to 10% of the general 
population will experience major depression during their lifetime (NICE, 2011) and 
are equivalent to those observed in a number of other conditions, including cancer 
(0%-58%) cardiovascular disease (range 20-50%) (Naylor et al., 2012) and diabetes 
(Anderson, Freedland, Clouse, & Lustman, 2001). The review also found that 
included studies reported 10-48% of participants as experiencing a comorbid anxiety 
disorder (any anxiety disorder), again comparable to levels seen in other conditions 
such as cancer (Linden, Vodermaier, Mackenzie, & Greig, 2012), and considerably 
higher than observed in the general population (where lifetime estimates suggest 5.7% 
will experience generalised anxiety disorder, 1.4% panic disorder, 12.1% social 
anxiety disorder) (NICE, 2011). These findings support those of a previous, 
unpublished, systematic review identifying that anxiety and depressive disorders are 
common (Kacorova, 2013).  
The results of the meta-regression indicated that depression is associated with 
outcomes to treatment, with severity of depressive symptoms found to be associated 
with less improvement in physical functioning from treatment. This result provides 
compelling evidence that depressive symptoms may be associated with poor outcomes 
to treatment, providing new weight to previous research (Bentall et al., 2002; Flo & 
Chalder, 2014). The findings further current knowledge, suggesting that this 
relationship may be specific to physical functioning outcomes, as a relationship 
between depression and fatigue was not identified. 
The findings have implications for the support and treatment of patients. It is known 
that CFS patients often face a variable prognosis, with recommended treatments 
having limited outcomes and focusing on management of symptoms, rather than 
treatment of the underlying pathogenesis of the condition, which is yet to be 
established. It is therefore important to understand factors associated both with quality 
of life of patients living with CFS, and factors associated with treatment outcomes. 
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These findings provide new evidence of the prevalence of anxiety and depression in 
Chronic Fatigue. It is already known that patients experiencing comorbid anxiety and 
depression are particularly vulnerable, being at risk of increased symptomology and 
disability, experiencing poor adjustment to illness and reduced quality of life (e.g. 
Cella et al., 2011; Cella et al., 2013; Moss-Morris et al., 2005). The review suggests 
that instead of viewing comorbidities as the exception, they should be treated as 
commonplace, and should be routinely assessed in clinical practice. These results 
indicate that, for patients to experience the highest quality of life, it is imperative that 
support adequately considers anxiety and depression and does not leave these needs 
unmet. 
The finding that depressive symptoms are associated with poorer improvement in 
physical function following treatment, has important implications for the treatment of 
patients experiencing comorbid depression. While it is not possible to infer causation 
or the mechanisms by which depression is associated with outcomes, these findings 
indicate that patients with depressive symptoms may benefit significantly from 
adapted interventions aimed at reducing depression, either concurrently or prior to any 
treatment for CFS. The new finding that this relationship is specific to physical 
function outcomes and not fatigue, has particular importance as  depression is known 
to lead to reductions in engagement and activity (e.g. Lewinsohn & Graf, 1973); in 
the case of CFS, it is possible that this might exacerbate any experiences of physical 
muscle deconditioning associated with reduced activity (Clark & White, 2005; 
Thyfault & Booth, 2011). Depression is also associated with low mood, lack of 
positive affect, loss of interest and enjoyment (American Psychiatric Publishing, 
2013), all of which may be barriers to engaging in treatment, and is also associated 
with poor sleep (Nutt, Wilson, & Paterson, 2008) known to be problematic in CFS 
(Krupp, Jandorf, Coyle, & Mendelson). Together, this suggests that depression should 
be targeted from the point of assessment, and clinicians should consider placing the 
emphasis more on behavioural aspects of the CBT intervention, mirroring successful 
depression interventions such as behavioural activation (Veale, 2018) to engage the 
patient and commence physical reconditioning and improve physical functioning. 
Interestingly, the study did not find evidence of anxiety moderating outcomes to 
treatment for CFS. This finding furthers previous research, which has failed to find 
evidence of an association between anxiety and CFS outcomes (Flo & Chalder, 2014), 
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and evidence that the association between anxiety and treatment outcomes in other 
health conditions is variable (DiMatteo et al., 2000). However, it is possible that the 
lack of relationship is in part attributable to the measurement of anxiety in the included 
papers, with all studies including non-specific measures of anxiety (five papers used 
the HADS, one used the BAI and the seventh used the A-State scale). It is known that 
anxiety is heterogeneous, consisting of multiple subtypes (American Psychiatric 
Publishing, 2013) and future research needs to explore whether specific anxiety 
disorders may be detrimental to outcome. For example, emerging research indicates 
that health anxiety is significantly associated with physical functioning (not fatigue) 
and furthermore, accounts for a significant proportion of the variance in physical 
function (Daniels & Salkovskis, in preparation). 
The current review has several strengths. It is the first systematic review to explore 
the prevalence of anxiety and depression across studies, and the first to report findings 
from meta-regressions exploring anxiety and depression as moderators of outcomes. 
It differentiates between different outcomes, exploring how comorbidities affect 
fatigue and physical function outcomes. It therefore makes a significant contribution 
to the knowledge base and advances our clinical understanding of the support and 
treatment of patients with CFS.   
There are also limitations to the current review that need to be considered. As only 
nine papers met the inclusion criteria, the meta-analyses and regressions were 
underpowered. While there was sufficient power to detect the relationship between 
depressive symptoms and physical function, the analysis might not have had sufficient 
power to detect any further relationships between anxiety and depressive symptoms 
and outcomes to treatment. In addition, baseline depression and anxiety scores were 
rescaled for inclusion in the regression models, to ensure they were on comparable 
scales. While this was unavoidable, it may have introduced sources of error as it is 
known the scales are not directly convertible (e.g. Applied Health Sciences (Mental 
Health), 2011) possibly resulting in heterogeneity of baseline variables. Furthermore, 
due to issues of power, trials of CBT and GET were combined within analyses; it is 
possible that the impact of anxiety and depression may be specific to certain 
treatments, leading us to have underestimated the impact in the current analysis. The 
funnel plots also indicated some asymmetry, suggesting there may be possible 
publication bias in the included studies. 
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There are further considerations that should be raised. The Cochrane risk of bias tool 
was chosen as the measure of quality assessment as it is provides a comprehensive 
assessment of bias in randomised clinical trials. However, the tool has limitations 
when applied to psychological research, including its lack of consideration of 
important issues such as treatment fidelity, and focus on other aspects such as blinding 
which are difficult in psychological research (Munder & Barth, 2018). A tool which 
explicitly considers features specific to psychological research may have been a useful 
addition to the review. An additional consideration is that the control group eligibility 
criteria included standard medical management and care, pharmacological therapy 
and non-CBT or GET psychological therapies, including relaxation or non-directive 
therapies. While a strength of the review is that the control group that best accounted 
for therapist attention was selected, to be able to specify the active treatment effect, it 
is possible that these varied control conditions had implications for the results. 
Importantly, three of the included studies used relaxation as the control condition. It 
is possible that relaxation may have had an effect on comorbid anxiety, possibly 
increasing the effectiveness of the control group if anxiety is associated with treatment 
outcomes. A final consideration is the inclusion of CBT and GET as the only two 
interventions of interest. These interventions were selected as they have the clearest 
empirical evidence of benefit, with there currently being insufficient evidence to 
recommend any other treatments (NICE, 2007). Given the context of the limited 
effectiveness of treatment, it is important that interventions with the best available 
evidence are explored to identify factors that may increase clinical effectiveness. 
Should an evidence base develop for other treatments, it may be useful to extend the 
current review to consider these interventions. 
The review raises several recommendations and future directions for both clinical 
practice and research. With regards to clinical practice, as previously described, the 
results suggest comorbidities should be anticipated and should be routinely assessed 
in clinical practice. While anxiety was not associated with treatment outcomes, 
previous research has highlighted it is associated with poor quality of life and 
symptom worsening, and therefore should be considered in patient care. For patients 
to experience the highest quality of life and to receive high quality care, it is 
imperative that support adequately considers anxiety and depression and meets these 
needs. With regards to future directions for research, as the current analysis explores 
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the relationship between depression and anxiety at a meta-, rather than individual- 
level, further research is needed if we are to fully understand the mechanisms by 
which depression affects treatment. Treatment trials should routinely index baseline 
depression and specific anxiety and assess the impact of these on treatment 
engagement, adherence and specific outcomes. This should be explored at the 
treatment-specific level, to explore whether the impact of comorbidities differs 
between treatment types. Supporting this, there is a need for consistent measurement 
of anxiety and depression if we are to accurately understand the impact of these 
comorbidities on treatment and outcomes. The recent introduction of the consistent 
use of the Hospital Anxiety and Depression Scale (Zigmond & Snaith, 1983) in the 
national dataset should go some way to resolve this, however the HADS is not without 
criticism (Cosco, Doyle, Ward, & McGee, 2012) and it is unclear whether it has 
diagnostic accuracy (Thombs et al., 2016) and, importantly, does not measure specific 
types of anxiety. 
In conclusion, this systematic review and meta-analysis provides evidence that 
comorbid depressive and anxiety disorders are common in Chronic Fatigue 
Syndrome. Severity of depression was found to be associated with poor treatment 
outcomes for physical functioning. The results have important implications for the 
wellbeing of patients, the identification of comorbid mental health difficulties, and the 
treatment of Chronic Fatigue.  
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Mind-maps are a graphical communication technique that has been found to enhance 
therapeutic work in substance misuse services. Despite their value in these settings, 
they have not been so frequently utilised in general mental health provision. To 
address this gap, a mind-map booklet, the “My Wellbeing Toolkit” was recently 
developed and introduced in an NHS Recovery Service. The current service 
improvement project aimed to explore uptake of the booklet and make 
recommendations for improvements to the booklet.  
A three-stage sequential explanatory mixed methods study was used to explore the 
evaluation questions: the initial stage involved collecting data on the number of care 
coordinators who had used the booklet, from existing logs, the second stage involved 
collection of questionnaire data on usage patterns of the booklet, the third involved 
collection of qualitative data on experiences of using the booklet. Quantitative data 
was explored using descriptive statistics; qualitative data was analysed using thematic 
analysis. 
Care coordinators identified that the booklet was useful for themselves and for clients, 
however uptake of the booklet was low. A number of barriers were identified: 
practical barriers, lack of confidence and clarity when using the booklet and a lack of 
client engagement. A series of recommendations were made to address these barriers 
and to improve the content of the booklet. 
The project suggests that mind-map booklets have considerable value for mental 
health provision, however support needs to be provided to clinicians to facilitate their 
use. Future directions for research include exploring client experiences of mind-map 
based booklets. 
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Introduction 
Mind-maps are a type of graphical communication technique (Dansereau & Simpson, 
2009), developed for use in substance misuse counselling as a tool to enhance 
treatment effects, based on their effectiveness in educational settings (Dansereau, 
2005).  
In clinical and mental-health practice, mind-map booklets were pioneered by, and are 
regularly used in, substance misuse services, for example the “Routes to Recovery” 
booklet published by Public Health England (2013). The development of mind-maps, 
and the evaluation of their use in the field of substance misuse, has been led by the 
Texas Christian University (Bartholomew & Dansereau, 2008), the UK Birmingham 
Treatment Effectiveness Initiative (BTEI) (Day, 2009) and the International 
Treatment Effectiveness Project (ITEP), sponsored by the UK National Treatment 
Agency for Substance Abuse (Public Health England, 2013).  
Mind-maps enhance therapy by organizing ideas and information spatially (Day, 
2015). The theoretical basis for mind-mapping is that verbal language is constrained 
by its linear nature, which limits the ability to draw links between complex concepts 
and ideas; in contrast, visual information allows more complex clustering and linkage 
of ideas (Day, 2015). Drawing on this, mind-mapping grew out of an observation that 
typical counsellor note-taking was providing counsellors with visual information and 
representations, however these were not being accessed by clients, and therefore client 
understanding was being limited. Mind-maps were developed to provide a common 
visual experience between both counsellor and client (Day, 2015). During clinical 
sessions they enable sharing of ideas, clarify information and maintain focus on a 
given topic (Day, 2015).  
Research has evidenced that mapping-enhanced counselling has benefits in increasing 
client motivation, engagement, participation, and retention in treatment (Dees, 
Dansereau, & Simpson, 1997; Joe, Dansereau, Pitre, & Simpson, 1997). Mind-maps 
have been found to promote more positive interactions with other clients and 
treatment staff, both in community-based and forensic settings (Pitre, Dansereau, 
Newbern, & Simpson, 1998). Outside of clinical sessions, mind-maps are suggested 
to enhance recall and confidence about material covered in sessions (e.g. Dansereau, 
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Joe, & Simpson, 1993; Dansereau, Dees, Greener, & Simpson, 1995; Knight, 
Dansereau, Joe, & Simpson, 1994; Newbern, Dansereau, Czuchry, & Simpson, 2005).  
However, despite their usage and value in educational and substance misuse settings, 
mind-map booklets are not currently routinely utilised in mental health services. This 
lack of provision is striking, particularly in the current context of mental health 
provision, where low-intensity interventions are prioritised in the early stages of a 
person’s care (NICE, 2011). To address this gap in service provision, a mind-map 
booklet (Avon and Wiltshire Mental Health Partnership NHS Trust, 2016) was 
recently developed and introduced for use by care coordinators in a Recovery Service 
in the South West of England, by a Clinical Psychologist working in adult mental 
health. 
The current project 
The current service improvement project aimed to explore uptake of the booklet and 
make recommendations, as necessary, for improvements to the booklet (Avon and 
Wiltshire Mental Health Partnership NHS Trust, 2016). To identify improvements, 
the project explored the clinician uptake and experience of the booklet, identified 
barriers to using the booklet and identified clinician opinions on how the booklet could 
be improved. Specifically, the project asked the following questions: 
1. Have Recovery Service care coordinators been routinely using the 
booklet with clients? 
2. Have care coordinators found the booklet helpful? If so, in what way? 
3. What have been the barriers and facilitators to using the booklet? How 
can these be improved? 
4. How do care coordinators think the booklet can be improved? 
It was anticipated the project would improve the quality of the booklet and would 
improve the processes for use. Specifically, it was expected that identifying barriers 
and facilitators to use would enable the service to address these. It was also expected 
that understanding clinician’s experiences of using the booklet and identifying their 
recommendations for improvement would improve the quality of the booklet. 
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Method 
Design 
A three-stage sequential explanatory mixed methods study (Cresswell, 2002) was 
used to explore the evaluation questions: the initial stage involved collecting data on 
the number of care coordinators who had used the booklet from existing logs, the 
second stage involved collection of questionnaire data on usage patterns of the 
booklet, the third involved collection of qualitative data on experiences of using the 
booklet. The project had relevant NHS trust service evaluation approval and 
University of Bath ethical approval (see Appendices G-I for relevant approvals) 
Participants 
Ten care coordinators in an NHS adult mental health Recovery Service completed the 
questionnaire. Seven care coordinators completed the focus groups (two focus groups 
were completed; two participants attended the first group, and five attended the second 
group), between March and October 2017. 
Materials 
Questionnaire pack. The questionnaire pack was developed for purpose and 
consisted of three sections described in Table 5 (see Appendix M for a copy of the 
questionnaire). 
Focus Group. The focus group used semi-structured questions to provide an 
in-depth understanding of the experience of using the booklet. The focus group 
included questions regarding the benefits of using the booklet, the barriers and 




Table 5. Table detailing contents of the questionnaire. 
Section Contents 
Section 1: Usage of 
the booklet and 
barriers/facilitators to 
use 
Quantitative questions identified the usage of the booklet, 
including frequency, regularity and patterns of usage. 
Qualitative questions provided space to describe barriers 
and facilitators to use. 
Section 2: Usefulness 
of the booklet 
Quantitative questions identified the perceived benefits of 
the booklet, including whether participants would 
recommend it to colleagues and clients. All questions 
included space to provide further qualitative feedback. 
Section 3: Improving 
the booklet 
Consisted of qualitative space for participants to make 
recommendations about improvements to the booklet. 
 
Procedure 
First stage. The initial stage of the evaluation involved collecting data on the 
number of care coordinators who had collected booklets in the first six months after 
it was introduced to the service. This data was collected from existing sign out sheets 
kept with the booklets.  
Second stage. The second stage of the evaluation involved collection of 
questionnaire data, completed approximately nine months after booklets were first 
introduced to the service.  
Care coordinators were given information sheets and brief verbal information about 
the evaluation during team meetings. As recruitment to the questionnaires was 
initially lower than hoped, three blocks of recruitment were completed. Consenting 
care coordinators completed the anonymous questionnaire pack identifying their 
experiences of using the booklet. Participants either completed the questionnaire pack 
during a team meeting, or in their own time, returning them either to the lead 
investigator during team meetings or to a designated drop-off location in the service. 
Once they had participated, participants were given a brief written debrief where they 
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were thanked for participating. Questionnaires contained no identifying information, 
and consent forms were stored separately.  
Third stage. The third stage of the evaluation was completion of two focus 
groups, nine and twelve months after the booklets were introduced to the service.  
Care coordinators who had agreed to be contacted were invited to participate in the 
focus groups via email. Consenting care coordinators attended a focus group, lasting 
approximately 30-45 minutes. Once completed, participants received a brief verbal 
and written debrief and were thanked for participating. Focus groups were audio-
recorded. 
Analysis 
Quantitative data from the questionnaire were explored using descriptive statistics.  
Thematic analysis was completed on qualitative data, following the steps described 
by Braun and Clarke (2006). Qualitative data from the focus groups and 
questionnaires were combined into one dataset, following Braun and Clarke 
recommendations (Braun & Clarke, 2006, 2018); data were combined as the data from 
the questionnaires and focus groups addressed the same research questions and asked 
the same questions of participants.  The two focus group interviews were transcribed 
from the audio-recordings. Preliminary immersion in the data involved repeated 
readings of all data, before initial codes were generated from the data, using NVivo 
version 10. Broader themes were then generated and reviewed before final themes and 
sub themes were identified.  
Thematic analysis was used as this method is not tied to any particular theoretical 
perspective, allowing flexibility in its approach (Braun & Clarke, 2006). A deductive 
approach was used, driven by the research questions: interpretation was confined to 
considering the broader meaning and significance of the themes in relation to the 
evaluation questions. There was no attempt to uncover latent meaning within 
participants’ language or discussion.  Despite this attempt, it is acknowledged that 
there is always an unavoidable impact of the researcher, on the design, data collection 
and interpretation of the data. As such, double rating was not completed: the use of 
inter-rater reliability is underpinned by the assumption that there is an accurate reality 
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in the data that can be captured through coding, with no impact of the researcher, 
which is not the case in thematic analysis (see Braun & Clarke, 2006). 
Results 
Quantitative analysis 
Usage patterns of the booklet. The log of the booklets indicated five care 
coordinators in the Recovery Service had signed out booklets to use.  
Three of the ten participants who returned the questionnaire reported that they had 
used the booklet. Between these three participants, they had used the booklet with 
eight clients. One participant reported using the booklet “occasionally”, another 
reported using at “approximately half the time” and the third did not provide a 
response.  
When the booklets were not used with clients, six participants reported that they had 
not suggested using the booklet to their clients, one reported that they had suggested 
using it, but the client declined, two reported that the timing was not appropriate for 
their clients.  
Usefulness of the booklet. The majority of questionnaire respondents had not 
used the booklet with clients. Of the available data, both participants who recorded 
using the booklet, reported that it was useful across all five dimensions (see Figure 7).  










Figure 7. Graphs showing questionnaire responses.  
N/A = participant indicated they had not used the booklet and were therefore unable 
to comment on its usefulness. 
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Qualitative analysis: thematic analysis 
Three main overarching themes were identified from the thematic analysis: benefits 
of the booklet, barriers to use and suggestions for improvement to the booklet. 
Benefits of the booklet. Participants in the focus groups described finding the 
booklets useful and a “great resource”. Within the over-arching theme of ‘benefits of 
the booklet’, two subthemes were identified: ‘benefit to the client’ and ‘benefit to the 
clinician’.  
Benefit subtheme one: benefit to the client. Several care coordinators 
described that clients found the booklet helpful, and that it contained useful content, 
including coping strategies and understanding strengths and weaknesses: 
“It's been useful... when they're [the client] reviewing it regularly… to learn some 
coping strategies and understand what their strengths and weaknesses are, it's really 
useful.” 
In addition, some care coordinators described that the booklet was helpful for complex 
clients, or those with particular needs, including those with a diagnosis of personality 
disorder.  
“Some of the people that I've given this to with personality disorder have actually 
found it very helpful, because it's something that they can then have control over. It's 
something they can look at and work on, and it's very much their thing.” 
One care coordinator commented that, even when a client initially found it difficult to 
engage with support, with encouragement the booklet had been useful: 
“Because one lady I've got really struggles with motivation, and with her, I have to 
really prompt her to get it out and have a look at it. But kind of keeping on at that time 
and again, it does seem that some of the information is sinking in a little bit, and she 
is a bit more motivated to look at it”. 
Benefit subtheme two: benefit to the clinicians. As well as benefiting clients, 
care coordinators felt that the booklet benefited themselves  
They felt that, if used correctly, the booklet could support them to get to know a client 
better, and to learn about their background, goals and insight: 
      45 
“I did this more as an ability to try to get to know them … and getting to know their 
insight into their life” 
They also thought that the booklet could support the care a client received from the 
service, in particular care planning. They also thought that it would have value for 
other professionals, particularly with regards to transfer of care or hospitalisations: 
“It's also a nice thing as part of the discharge, actually, especially writing a letter to 
the GP, or if primary care liaison picks up, at another stage, that this tool has been 
used, and potentially, there's a sharing possibility.” 
Barriers to using the booklet. A theme of barriers to using the booklet was 
identified, with a number of care coordinators noting that they had not used the 
booklets. Within the theme of barriers to use, three subthemes were identified: 
practical barriers, lack of clarity and confidence using the booklet, and lack of client 
engagement,  
Barriers subtheme one: Practical barriers. A number of care coordinators 
were not aware of the booklet or did not know where to collect the booklets from, or 
knew how many they could have: 
“I … was unaware of the booklets” 
“Partly, I think, there was a sense that we were perhaps allowed one” 
 “Sometimes, it's kind of like, "Where are they kept?" or running around to try to find 
them.” 
Barriers subtheme two: Lack of clarity and confidence over the application 
of the booklet. A key subtheme that came up was that a lack of clarity over the purpose 
and application of the booklet was experienced as a barrier to using it.  
“I suppose, yes, there is an element… about the training behind it, like what is the 
purpose of it, I think, maybe, needs to be clearer … "When do I use it? Why am I using 
it? What's the purpose of these?" 
“I think it's a very, very difficult one all round, if I'm being honest, because it is about 
when do you pick it up? Why do you pick it up? When do you review it? How is the 
service user using it?” 
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Care coordinators spoke about a lack of confidence in terms of knowing whether they 
should be completing it with clients, or if clients were meant to complete it 
independently: 
 “The title "My wellbeing booklet" … makes some [service users] feel it is for them to 
complete by themselves” 
Some participants explained that this lack of understanding of the purpose of the 
booklet was compounded by other work-based pressures, which meant they prioritised 
mandatory work, and did not take up opportunities to use or explore the booklet: 
“[A barrier is] lack of time and having already commenced other pieces of work with 
service users whom I have been allocated for a while” 
“I think it's probably because it's, sadly just another thing we have to pick up. It's not 
like a mandatory thing; it's more like something that's there that's optional to use. You 
just sometimes just don't opt into having another thing to use.” 
Barriers subtheme three: Lack of client engagement. Care coordinators 
described that some clients did not want to use the booklet, and that if a client was not 
engaged they did not bring the booklet to sessions: 
“Yes, I've been clear about getting them to bring it back, and that we could use it in a 
session. But yes, when they've not brought it back, and just not knowing, really, where 
we were going with it, at that point.” 
“The [booklets] I've given out, they then don't bring it back.” 
Improvements to the booklet. Two subthemes were identified within the 
theme of improvements for the booklet: suggestions for additional content in the 
booklet, and suggestions for improving accessibility and guidelines about using the 
booklet.  
Care coordinators liked the layout and design of the booklet, and thought it was user 
friendly. They liked that it did not contain jargon, and that it could be photocopied for 
repeated use.  
Suggestions for improvement one: Additional content. Care coordinators 
suggested the following additions to the booklet: 
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1. Additional information about online/email/text support services, for self-harm 
and mental health difficulties: 
“[Information on] online support for self-harm. I know that some people have 
had difficulty with phone-in services There are some quite good online- …. I'm 
just wondering if they're in here for people that aren't able to phone and make 
that contact.” 
“You've got a couple of apps, but …I know there are some support services 
where you can have email support or text support instead of phoning them, if 
you need to.” 
2. Information on the role of attachment in mental health difficulties: 
“For me, something on attachment would be helpful, because I think that often 
underlies those difficulties we work with… maybe thinking about their own 
styles and exploring curiosity around that.” 
3. Information on the experience of hearing voices 
“A section on psychosis: hearing voices, delusions, and that sort of thing… At 
Recovery Team level, it's fairly common. Yes, at this level of service, I think it 
would be really important.” 
4. A page to record contact details of professionals involved in clients’ care 
There were two suggestions that the format of the booklet could be improved. It was 
suggested that the booklet could be developed into an electronic app or pocket-sized 
version. 
There was also a suggestion that modifying the booklet to allow progress and change 
to be logged would be useful, and that this might be facilitated through changing the 
binding of the booklet to allow pages to be slotted in: 
There was one suggestion that the wording of a particular page, the “discovery page” 
could be changed, otherwise care coordinators thought that nothing should be 
removed from the booklet. 
Suggestions for improvement two: accessibility and guidelines about using 
the booklet. It was recommended that the booklet will be most helpful at initial entry 
into the service and at discharge, and that use of it should be led by the client, who 
should be allowed to opt in or out of the booklet. 
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To ensure the booklet is accessible, it was suggested that the booklet should be left in 
the admin office or put with new referral packs. 
It was suggested that a training session could be scheduled, using an example case to 
demonstrate use of the booklet. 
Outcomes: feedback, recommendations and next steps 
It was fed back to the service during a meeting with the booklet developer, that care 
coordinators felt that the booklet had several benefits for both clients and care 
coordinators, but that uptake of the booklet had been low. The barriers to using the 
booklet were discussed, as well as the recommended improvements of how to address 
these. The recommendations for addressing barriers to use are summarised in Table 
6. 
Table 6. Table listing recommendations for addressing barriers to use of the booklet. 
Barriers to use: Recommendations: 
Practical barriers  Service should consider keeping the booklets in an accessible 
location that care coordinators are aware of. 
Service should consider providing the booklets to care 
coordinators when they receive a new referral. 
 Service should consider regularly reminding care 
coordinators of booklets, to ensure that use continues. 
The lack of clarity 
and confidence 
over the 
application of the 
booklet 
Service should consider holding training sessions covering: 
1. Information on the intended purpose of the booklet 
2. Information and discussion of how best to use the 
booklet with clients (for example at intake and 
discharge from the service) 
3. Information and discussion on how to use the booklet 
with more complex clients, and how to consider who 
the booklet might be appropriate for 
Service should consider providing regular drop-in sessions 
for clinicians to access supervision and support on how to use 
the booklet, and troubleshooting. 
Lack of client 
engagement 
Service should recognise that the booklet won’t be 
appropriate for all clients, and clients should have the option 
to decline to use the booklet. 
Service should consider the above recommendations to 
address practical barriers and the lack of confidence and 
clarity as a means of improving clinician engagement with the 
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booklet, thereby improving the motivation to use the booklet 
during sessions. 
Service should consider gathering client feedback on the 
booklet in the form of a future service improvement project 
or review, to explore whether the booklet is perceived as 
useful by clients, and when in their support it is useful 
 
The following recommendations were also made for a possible second edition of the 
booklet: 
1. To consider including: 
a. Additional content on attachment 
b. Additional content on experiences of hearing voices 
c. Details of email and text support services on the page of services, as 
well as talking therapies 
d. A front page with space to record contact details of involved clinicians 
2. To consider changing the format of the booklet to allow insertion of extra 
sheets 
3. To consider development of an electronic app version of the booklet 
Feedback from the service 
The service fed back that the project had been very useful and had furthered the use 
of the booklet. They intended to take the recommendations forward, particularly those 
to address the barriers to use, and hoped to introduce the booklet to new teams in the 
Trust. 
Next steps and further research 
With regards to next steps, the service intended to meet with the Trust Clinical 
Commissioning Group to feedback clinicians’ experiences of using the booklet, make 
a case for introducing the booklet to new teams within the Trust and suggest 
recommendations for improvement. To facilitate this, a one-page summary of the 
service improvement project was drawn up and provided to the service (see Appendix 
O).  
It was recommended that a future evaluation should be considered to identify whether 
the recommendations of the current project have improved usage and uptake of the 
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booklet. It was also recommended that the service should consider gathering client 
feedback on the booklet in a future service improvement project, to ensure the booklet 
is perceived as useful by clients. It is possible that identifying if clients find the booklet 
helpful, would improve uptake of the booklet by clinicians by addressing the 
perceived barrier of lack of client engagement. These projects would provide further 
evidence of the value of mapping enhanced mental health support. 
Discussion and implications 
The current project aimed to explore uptake of the “My Wellbeing Toolkit”, a mind-
map based booklet recently introduced to the Recovery Team and recommend 
improvements to the booklet.  
The project identified that usage of the booklet had been low within the Recovery 
Service, and that clinicians had not been routinely using the booklet. However, despite 
the low uptake, clinicians identified a number of benefits of the booklet, reporting the 
booklet was useful for both clinicians and clients. They thought the booklet was user-
friendly, provided a platform for them to get to know their clients and also aided with 
information sharing between professionals. Participating care coordinators thought 
the booklet contained useful content for clients and that it was suitable for a range of 
psychological difficulties. Three primary barriers to use were identified, that may have 
contributed to the low uptake of booklet: practical barriers, lack of clarity and 
confidence over the application of the booklet. and lack of client engagement. 
Participants made a series of recommendations for improvements. Based on these 
findings, recommendations were made to the service to address barriers to use and for 
improvements to the booklet content. The findings were well received and accepted 
by the service, who intended to take the recommendations forward. 
The project suggests mind-map based booklets such as the “My Wellbeing Toolkit” 
have value for mental health provision. While these booklets have been previously 
used in substance misuse services (Public Health England, 2013) they have not been 
extensively used in general mental health recovery services. Previous research has 
identified mind-map based tools have a number of benefits (Dansereau et al., 1993; 
Dees et al., 1997; Joe et al., 1997; Pitre et al., 1998). The current project found that in 
mental health settings mind-map booklets have considerable value for both clinicians 
and clients. However, the project also identified there may be service-level barriers to 
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implementing booklets which need to be considered if booklets are to be successfully 
introduced into services.  
Strengths, limitations and further considerations  
The project has a number of strengths. The use of qualitative analysis means it was 
possible to gather a rich understanding of experiences of using the booklet, to make 
recommendations of how it could be improved. The project met its objectives and is 
the first to provide a specific evaluation of the use of mind-map based booklets in 
non-substance misuse secondary care mental health services. There are limitations 
that should be considered. It is possible that the record of the number of clinicians 
who had used the booklet may have underestimated their use, as clinicians might have 
taken booklets without signing them out and as participation in the current project was 
optional for care coordinators. Despite multiple attempts to recruit to the 
questionnaire, inviting all care coordinators within the team to participate on a number 
of occasions, only ten care coordinators did so and only two could give data on their 
usage patterns. This meant that the sample size was relatively small and may not have 
provided an accurate account of usage within the service. Making the questionnaire 
compulsory would have raised significant ethical considerations, and therefore we 
were reliant on participants volunteering.  There are also limitations to using a 
questionnaire that was designed for purpose, as it does not have any reliability or 
validity statistics, however although it does allow tailoring to the specific project aims. 
An additional limitation is that as the evaluation focused solely on the clinician 
experiences of the booklet, it does not give insight into client experiences of the 
booklet.  
With regards to other considerations, it is important to note that the focus groups 
consisted of a mix of clinicians who had and had not used the booklet. While this 
reflected the limited uptake of the booklet, it is possible that this affected the findings 
as a number of participants had no experience of using the booklets, and therefore will 
not have had direct experience of any benefits or disadvantages of use. However, 
importantly, these clinicians were able to provide comprehensive information on the 
barriers they experienced to use. Had uptake of the booklet been greater, with a larger 
available participant pool, it may have been more appropriate to complete separate 
focus groups with participants who had and had not used the booklets. 
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It can also be questioned whether the focus group schedule or analysis method were 
most appropriate for this project. Considering the high overlap between the questions 
asked in the focus groups and questionnaires and the themes generated, it could be 
suggested that the themes identified are less reflective of general themes and instead 
more descriptive (Vaismoradi, Turunen, & Bondas, 2013). It is therefore possible that 
content analysis might have been a more appropriate analytic approach for the data 
(Vaismoradi, Turunen, & Bondas, 2013). Furthermore, the focus groups focused 
exclusively on the particular toolkit and questions were specific and service focused. 
It is therefore possible that the themes identified cannot be generalised beyond the 
scope of the individual “My Wellbeing Toolkit” resource. To increase 
generalisability, it may have been more appropriate to complete a focus group or 
interviews on broader ideas and views of working with clients using mind-map based 
tools, to provide a richer understanding of these types of resources, as opposed to this 
particular booklet. This could then be analysed with IPA on a smaller sample of 
participants.  
Summary and conclusions 
The current project aimed to make recommendations for improvement for the “My 
Wellbeing Toolkit”, a mind-map based booklet recently introduced to the Recovery 
Service. The project identified a number of benefits of using the booklet, for both 
clinicians and clients, however uptake of the booklet was low. Three main barriers to 
using the booklet were identified. Recommendations of how to address these barriers 
were made, in addition to recommendations for additional content that could be 
included in a future edition of the booklet.  
In conclusion, the current project suggests that map-based booklets have value for 
mental health services, however thought needs to be given as to how to ensure that 
they are used within teams. The findings suggest that there may be simple and 
manageable ways to reduce barriers to uptake, and that, when used appropriately, both 
clinicians and clients can benefit from mind-maps in mental health services. 
  
      53 
References 
Avon and Wiltshire Mental Health Partnership NHS Trust. (2016). My Well-being 
Toolkit.   
Bartholomew, N. G., & Dansereau, D. F. (2008). Mapping-Enhanced Counseling: An 
Introduction. In T. I. o. B. R. a. TCU (Ed.). 
Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative 
Research in Psychology, 3(2), 77-101.  
Braun, V., & Clarke, V. (2018). Thematic analysis.   Retrieved 1st April, 2018 
Cresswell, J. W. (2002). Research Design: Qualitative, Quantitative, and Mixed 
Methods Approaches (2nd Edition ed.): SAGE Publications. 
Dansereau, D., Joe, G., & Simpson, D. D. (1993). Node-link mapping: A visual 
representation strategy for enhancing drug abuse counseling. J. Couns. 
Psychol., 40(4), 385-395.  
Dansereau, D. F. (2005). Node-link mapping principles for visualizing knowledge and 
information. In S. O. Tergan & T. Keller (Eds.), Knowledge and Information 
Visualization (pp. 61-81): Springer-Verlag. 
Dansereau, D. F., Dees, S. M., Greener, J. M., & Simpson, D. D. (1995). Node–Link 
Mapping and the Evaluation of Drug Abuse Counseling Sessions. Psychology 
of Addictive Behaviors, 9(3), 195-203. doi: 10.1037/0893-164X.9.3.195 
Dansereau, D. F., & Simpson, D. D. (2009). A picture is worth a thousand words: The 
case for graphic representations. Professional Psychology: Research and 
Practice, 40(1), 104-110. doi: 10.1037/a0011827 
Day, E. (2009). The Birmingham Treatment Effectiveness Initiative (BTEI) An 
Introductory Guide. 
Day, E. (2015). What Is… Node-link Mapping?   Retrieved 2nd Feb 2018 
Dees, S. M., Dansereau, D. F., & Simpson, D. D. (1997). Mapping-enhanced drug 
abuse counseling: urinalysis results in the first year of methadone treatment. J 
Subst Abuse Treat, 14(1), 45-54.  
Joe, G. W., Dansereau, D. F., Pitre, U., & Simpson, D. D. (1997). Effectiveness of 
node-link mapping enhanced counseling for opiate addicts: a 12-month 
posttreatment follow-up. J Nerv Ment Dis, 185(5), 306-313.  
54 
Knight, D. K., Dansereau, D. F., Joe, G. W., & Simpson, D. D. (1994). The role of 
node-link mapping in individual and group counseling. American Journal of 
Drug and Alcohol Abuse, 20(4), 517-527. doi: 10.3109/00952999409109187 
Newbern, D., Dansereau, D., Czuchry, M., & Simpson, D. (2005). Node-Link 
Mapping in Individual Counseling: Treatment Impact on Clients with ADHD-
Related Behaviors. Journal of Psychoactive Drugs, 37(1), 93-103. doi: 
10.1080/02791072.2005.10399752 
NICE. (2011). Common mental health problems: identification and pathways to care: 
Clinical guideline [CG123].  
Pitre, U., Dansereau, D. F., Newbern, D., & Simpson, D. D. (1998). Residential drug 
abuse treatment for probationers. Use of node-link mapping to enhance 
participation and progress. J Subst Abuse Treat, 15(6), 535-543.  
Public Health England. (2013). Routes to Recovery. 
 
  
      55 
 
 
Main Research Project - HPV-related shame, stigma, 
depression and anxiety in women with cervical 
cancer 
Amy J Caswell 
a.caswell@bath.ac.uk 
Internal supervisors: Dr Cara Davis & Dr Megan Wilkinson-Tough 
External supervisor: Dr Samantha Cole 
Word count: 4392 
Date of report: 16th May 2018 
 
Journal structure: Psycho-Oncology (See Appendix P for journal guidelines; all 
formatting is in line with journal recommendations) 
Note: Journal requires numbered references – these have been changed to APA 6th 
formatting for the purposes of this portfolio, to meet university requirements and to 
maintain consistency throughout the portfolio. 





Cervical cancer patients are at particular risk of experiencing psychological distress 
and mental health difficulties. The current study investigated whether this is 
associated with knowledge of the sexually-transmitted nature of HPV, exploring 
HPV-related shame, anxiety and low mood in women with cervical cancer.  
110 women with cervical cancer completed a repeated measures study, during which 
they read information that HPV is (1) considered to be a sexually-transmitted virus 
and (2) very common. Participants completed measures of shame, mood and anxiety 
after each level of information.  
The results indicated that information that HPV is sexually-transmitted is associated 
with experiences of shame. Increased shame was associated with depression, low 
mood, anxiety and poor wellbeing. Women with a history of depression and anxiety 
were at particular risk for experiencing high levels of shame.  
The results indicate that women with cervical cancer experience high levels of shame 
related to HPV information. This has implications for how to support patients who are 
at risk of experiencing high levels of shame, particularly around HPV-information 
provision, identifying at-risk patients, and the psychological support of patients. 
 
Key words 
Anxiety; Cancer; Cervical Cancer; Depression; Human Papilloma Virus; HPV; 
Oncology; Psychology; Shame;  
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Introduction 
Background 
There are over 3000 new cases of cervical cancer in the UK each year. Cervical cancer 
is considered a “preventable” cancer; close to 100% of cases are associated with high-
risk strains of a common infection, Human Papilloma Virus (HPV), transmitted 
through intimate skin-to-skin contact during sex (Cancer Research UK, 2016). HPV 
is very common, and it is estimated that at least 80% of people will contract the virus 
at some point in their life.  
Research has indicated that cervical patients are at particular risk of experiencing 
anxiety, depression and other mental health difficulties, over and above the general 
population (Bradley, Rose, Lutgendorf, Costanzo, & Anderson, 2006) and patients 
with other gynaecological cancers (Bradley et al., 2006). Factors that have been 
implicated in this risk for psychological distress include the related constructs of 
shame and stigma. It is known that HPV diagnosis is associated with shame, anxiety 
and distress (Kahn et al., 2007; Maissi et al., 2004). A recent survey found that 20% 
of women associated gynaecological cancers with sexual promiscuity and close to 
40% of women felt that gynaecological cancers are particularly stigmatised types of 
cancer. In the same survey, over one third of women thought that reducing shame and 
stigma around gynaecological health and sex would enable them to talk more openly 
about such health issues (The Eve Appeal, 2015). 
Shame is a complex, multi-faceted experience that can be both externally focused (i.e. 
focusing on what others think about the self, referred to as ‘external shame’, e.g. 
“others think I am a bad person”) and internally focused (i.e. focusing on what the 
person thinks about themselves, referred to as ‘internal shame’, e.g. “I am a bad 
person”) (Gilbert, 2006). As these two types of shame are considered closely related, 
they are often collectively be referred to as shame, with much literature failing to 
differentiate between the two (Gilbert, 2006). Shame is typically associated with a 
strong emotional response, for example anxiety, anger and disgust (Gilbert, 2006). 
Shame is considered to be strongly related to cultural values (Gilbert, 2006), which 
has particular implications for understanding experiences of shame in women with 
cervical cancer. As previously described, cervical cancer is associated with HPV, a 
sexually-transmitted virus (an STI), and the risk of HPV increases with number of 
58 
partners. In Western society,  ‘permissive’ values in sexual relationships, i.e. having 
multiple or casual sexual partners, remains culturally stigmatised (e.g. Vrangalova, 
Bukberg, & Rieger, 2014) and there is evidence that this stigma extends directly to 
cervical cancer, with patients in a vignette being rated by others as more “dirty”, 
“dishonest” and “unwise”,  and triggering feelings of moral disgust, when HPV is 
specified as the cause (Shepherd & Gerend, 2013). 
Research has found that this cultural stigma may be associated with individuals’ 
experiences of HPV-related shame. A quasi-experimental study found that non-
clinical participants experienced higher levels of shame and stigma when asked to 
imagine their reaction to a hypothetical HPV diagnosis, when told HPV is sexually-
transmitted, compared to reduced shame when told HPV is very common (Waller, 
Marlow, & Wardle, 2007). Further qualitative research with HPV positive women, 
who do not have a diagnosis of cervical cancer, found that testing positive for HPV 
was associated with feelings of stigma, primarily linked to the sexually-transmitted 
nature of the virus, and its association with cervical cancer (McCaffery, Waller, 
Nazroo, & Wardle, 2006). The same research  indicated that knowledge of the high 
prevalence of HPV might reduce experiences of shame around their diagnosis 
(McCaffery et al., 2006). 
In addition to feelings of stigma, McCaffery and colleagues (2006) found HPV 
positive women also experienced higher levels of anxiety and stress. This suggests 
that HPV-related shame may be associated with poorer wellbeing. While there is no 
research specific to cervical cancer, shame and stigma are known to be related to 
poorer quality of life and higher psychological distress in lung cancer (Chambers et 
al., 2012) and there is evidence that shame is particularly associated with depression 
in cancer more generally (Kim, Thibodeau, & Jorgensen, 2011).  
The current study 
Despite the above research, there has previously been no examination of how women 
with cervical cancer experience information about HPV. It is not known whether 
knowledge that HPV is sexually-transmitted is associated with internal or external 
shame or poor mental wellbeing, or whether information that HPV is very common 
normalises the experience of having HPV and reduces internal or external shame. It 
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is also not known whether internal or external shame is associated with an increased 
risk of psychological distress and mental health difficulties in patients. 
The current study aimed to address these questions by presenting information about 
HPV and measuring psychological experiences of participants. The research 
questions, and related hypotheses, are presented in Table 7.  
Table 7. Table presenting study research questions and related hypotheses 
Research question Related hypotheses 
Is shame in cervical cancer 
associated with knowledge that 
HPV is sexually-transmitted? 
Pre-existing knowledge that HPV is sexually-
transmitted would be associated with higher 
baseline levels of shame. 
Activation of knowledge that HPV is sexually-
transmitted would be associated with increased 
shame. 
Does information that HPV is 
very common reduce experiences 
of shame in women with cervical 
cancer? 
Pre-existing knowledge that HPV is very 
common would be associated with lower levels 
of baseline shame. 
Activation of knowledge that HPV is very 
common would be associated with reductions 
in state shame. 
Is shame associated with 
increased depression and anxiety 
in women with cervical cancer? 
Activation of knowledge that HPV is sexually-
transmitted would be associated with 
reductions in mood and wellbeing and 
increases in levels of anxiety. 
Activation of knowledge that HPV is very 
common would be associated with an increase 
in mood and wellbeing and reduction in 
anxiety. 
Higher levels of shame at baseline would be 
associated with higher depression and anxiety 
at baseline. 
History of depression and anxiety would be 
associated with higher levels of shame at 
baseline. 
Note - In all hypotheses “shame” refers to internal and external shame, both of which 
were measured separately. There was no specific hypothesis as to whether internal or 
external shame differed within any of the above research questions. 
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It was anticipated that findings could help clinicians to better understand the 
emotional experiences of patients, not only helping inform how they provide 
information, but also how they support them through the information, diagnosis and 




One hundred and ten women with cervical cancer completed the current study. 
Participants were recruited through online sources, including the Jo’s Cervical Cancer 
Trust charity website, social media platforms, including Facebook and Instagram, 
other women’s health charity and support websites, and through two NHS 
gynaecological-cancer centres. 
Participants were required to be women fluent in English, over the age of 25, with a 
past or current diagnosis of cervical cancer. Women concerned that they have cervical 
cancer but with no confirmed diagnosis were not eligible to participate. 
An a priori power analysis, using G-Power version 3.1.5, indicated that 110 
participants would be required to have 80% power for detecting a small-sized effect 
for the primary hypothesis, with the traditional .05 criterion of statistical significance.  
Design 
The study used a repeated measures design adapted from Waller, Marlow and 
Wardle’s design (Waller et al., 2007). 
The study had ethical approval from the Health Research Authority (IRAS 217863; 
REC reference 17/WA/0106) and the University of Bath (approval code 17‐133). See 
Appendices Q-S for copies of ethical approval notifications. 
Procedure 
The study was completed online via Qualtrics survey software. Participants provided 
informed consent at the beginning and end of the study, self-confirming that they met 
inclusion criteria (see Appendix T & U) 
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Participants first completed a demographic questionnaire, cancer demographic 
questionnaire, measure of lifetime depression and anxiety, the Hospital Anxiety and 
Depression Scale, the Warwick-Edinburgh Mental Wellbeing Scale, the State Shame 
and Guilt Scale (SSGS) and the Modified State Shame and Guilt Scale (MSSGS). 
They then completed a multiple-choice quiz identifying their baseline knowledge of 
HPV, including transmission and prevalence of HPV.  
Participants were then presented with three different levels of information about HPV. 
The first level of information (“general” information) explained that cervical cancer 
is associated with HPV. The second and third levels of information stated that HPV 
is sexually-transmitted (“STI” information), and that the virus is extremely common 
(“common” information). See “materials” for details of the different levels of 
information. Presentation of “STI” and “common” information was counter-balanced, 
with half of the participants receiving “STI” information first and half receiving the 
“common” information first, achieved via Qualtrics randomiser.  
After each level of information, participants repeated the SSGS, MSSGS and brief 
mood ratings. To ensure they were linked with the information, questions were 
presented directly referencing the information the participant just read, for example 
“When I think about the information XXX, I feel XXX”. 
Finally, participants completed a manipulation check in the form of a brief version of 
the multiple-choice quiz. This was to allow the authors to check that all participants 
had correctly understood the HPV information. 
Once participants had completed the protocol they were debriefed. Participants were 
not directly reimbursed for their participation, instead a charity donation of £1 was 
made for each participant. 
Materials 
HPV information 
“General” information consisted of the following statement: 
“A virus called human papillomavirus (HPV) is now known to be involved in the 
development of cervical cancer (cancer of the cervix or neck of the womb).  
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For most women, the immune system clears the virus and there are no health problems 
associated with it.  
However, if infection persists, it can lead to abnormalities in the cells of the cervix.  
These cells then have an increased risk of becoming cancerous.” 
“STI” information consisted of the statement: 
“HPV is transmitted through intimate skin-to-skin contact during sex. It is sexually-
transmitted.” 
“Common” information consisted of the statement: 
“HPV is very common. It is estimated that currently around 80% of people will be 
infected with HPV at some point in their lives. That means that of every 5 people you 
know, approximately 4 will have had the virus.” 
Demographic questionnaire. The demographic questionnaire asked for 
general information, including the participant’s age, country of residence, ethnicity, 
education, relationship status, and history of depression and anxiety. History of 
depression and anxiety was recorded using the following two brief items, adapted 
from the Structured Clinical Interview for DSM-IV (First, Spitzer, Gibbon, & 
Williams, 2002): 
1. Have you ever had a period of time during your life when you were feeling 
depressed or down most of the day, nearly every day? (a) Yes, once (b) Yes, 
more than once (c) No 
2. Have you ever had a period of time during your life when you were feeling 
very anxious or worried most of the day, nearly every day? (a) Yes, once (b) 
Yes, more than once (c) No 
Cancer demographic questionnaire. The cancer demographic questionnaire 
asked for cancer specific information, including type and stage of cervical cancer, and 
treatments.  
Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983). 
The HADS is a 14-item questionnaire measuring current anxiety and depression. The 
primary outcome variables are total scores for anxiety and depression; scores range 
      63 
from 0-21, with scores of 8 or more indicating clinical caseness  (Bjelland, Dahl, 
Haug, & Neckelmann, 2002). 
Warwick-Edinburgh Mental Well-Being Scale (WEMWBS; NHS Health 
Scotland, 2006). The WEMWBS is a 14-item questionnaire measuring psychological 
well-being. The primary outcome variable is wellbeing; scores can range from 15-70, 
with higher scores indicating better wellbeing 
State Shame and Guilt scale (SSGS; Marschall, Sanftner, & Tangney, 
1994). The SSGS is a 15-item questionnaire measuring internal shame, guilt and 
positive affect. For the purposes of the current study, the primary outcome variable is 
internal shame; guilt and positive affect are not relevant to the current study and so 
will not be discussed.  
Modified State Shame and Guilt scale (MSSGS; adapted from  Marschall 
et al., 1994). To index external shame, the 15-item SSGS was modified to identify 
how the participant believes other people feel about them, rather than how the 
participant feels about themselves (i.e. external shame, rather than internal). The 
primary outcome variable is external shame.  
Multiple-choice quiz (MCQ).  The MCQ consisted of 9 multiple-choice 
items, developed by the authors, to establish participants’ baseline knowledge about 
cervical cancer and HPV. Six items were included as fillers, three items identified 
whether participants were aware cervical cancer is associated with HPV and that HPV 
is sexually-transmitted, and whether they had an accurate understanding of the 
prevalence of HPV. 
Brief Multiple-choice quiz (brief MCQ). The brief MCQ was a 3-item 
version of the MCQ, in which the six filler items were removed, and three items 
identified whether participants were aware cervical cancer is associated with HPV and 
that HPV is sexually-transmitted, and whether they had an accurate understanding of 
the prevalence of HPV. 
Brief mood ratings. Brief mood ratings of low mood, anxiety and wellbeing 
were recorded using 0-10 scales to identify participants’ current mood, developed by 
the authors. 
Please see Appendices W-Y for copies of all non-copyrighted materials. 
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Statistical analysis 
All data were explored using IBM SPSS Statistics, version 22. Answers on the Brief 
MCQ were first checked, to exclude any participants who had not correctly 
understood the HPV information by the end of the study.  
Demographics. Participant general and cancer-specific demographics were 
explored using descriptive statistics.  
Knowledge of HPV information. Correct answers on the MCQ at baseline 
were explored using descriptive statistics, to identify how many participants had pre-
existing knowledge that cervical cancer is associated with HPV, and that HPV is 
considered a sexually-transmitted infection. Descriptive statistics were also used to 
explore participants’ estimates of the prevalence of HPV in the general population. 
Association between HPV knowledge and feelings of shame. The 
association between HPV knowledge and feelings of shame was explored both at 
baseline (i.e. pre-existing knowledge) and following activation of knowledge during 
the study.  
Pearson’s correlations were performed to explore whether there was a relationship 
between baseline estimates of HPV prevalence and internal and external shame. One 
further comparison was planned between those correctly identifying HPV as sexually-
transmitted and those who did not know this fact at baseline on the MCQ. However, 
as all participants were correct, this was not possible. 
To explore the effects of activated information on levels of internal and external 
shame, repeated measures ANOVAs (baseline vs following “STI” information vs 
following “common” information) were performed; Bonferroni corrected post-hoc 
tests were performed to identify significant differences between the three time-points.   
Association between shame and depression, anxiety and wellbeing. 
Pearson’s correlation coefficients were run to explore whether there was a significant 
relationship between baseline internal and external shame on the SSGS and MSSGS, 
and experiences of depression and anxiety (as recorded on the HADS) and wellbeing 
(on the WEMBWS).  Women who recorded that they had experienced multiple 
episodes of depression and anxiety in their lifetime were compared to those with no 
history, or a single episode, on measures of baseline shame using one-way ANOVA. 
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Paired samples t-tests were used to compare mood ratings following “STI” and 
“common” information (these ratings were not recorded at baseline). 
Results 
Participant demographics 
Participant demographics are presented in Table 8. 
Baseline cervical cancer knowledge 
In the baseline multiple-choice quiz, all participants (100%) correctly identified that 
cervical cancer is associated with HPV, and that HPV is primarily transmitted through 
intimate skin-to-skin contact, particularly during sex. Participants gave a mean 
estimate that 70.61% (SD 18.98; median 76%; range 9-100) of the population contract 
HPV at some point in their lifetime, where the correct estimate is approximately 80%.  
Association between HPV knowledge and feelings of shame 
Existing knowledge and experiences of shame. As all participants were aware 
that cervical cancer is associated with HPV, it was not possible to compare levels of 
shame between women who did and did not know.  
There was not a significant correlation between estimates of HPV prevalence and 












Table 8. Participant demographic information 
 Mean (s.d.) 
Age (years) 40.62 (9.98) 
HADS Depression 6.03 (3.92) 
HADS Anxiety 9.53 (4.36) 
 WEMWBS Wellbeing 43.87 (11.50) 
SSGS Internal shame 9.54 (4.62) 
MSSGS External shame 8.42 (4.29) 
 N (%) 
History of depression  
Yes, once 22 (20%) 
Yes, multiple 60 (63.6%) 
No 17 (15.5%) 
History of anxiety  
Yes, once 13 (11.8%) 
Yes, multiple 83 (75.5%) 
No 14 (12.7%) 
Education  
GCSE (or equivalent) 17 (15.5%) 
A level (or equivalent) 23 (20.9%) 
Undergraduate degree 38 (34.5%) 
Postgraduate degree 23 (20.9%) 
Prefer not to answer 9 (8.2%) 
Country  
UK 43 (39.1%) 
USA 50 (45.5%) 
Other 17 (15.5%) 
Ethnicity  
White 104 (94.5%) 
Mixed/multiple ethnic groups 3 (2.7%) 
Other 3 (2.7%) 
Relationship status  
Single 19 (17.3%) 
Committed or exclusive relationship 12 (10.9%) 
Married or domestic partnership 70 (63.6%) 
Widowed 3 (2.7%) 
Divorced or separated 6 (5.5%) 
Cervical cancer diagnosis  
Squamous cell cancer 43 (39.1%) 
Adenocarcinoma 36 (32.7)) 
Other 31 (28.2%) 
Cervical cancer stage  




      67 
Activated knowledge and experiences of shame. There was a significant 
effect of type of information on levels of internal shame on the SSGS, F(1.785, 
187.414)=14.320, p<.001; df huynh-feldt corrected.  Shame was significantly higher 
after reading information that HPV is sexually-transmitted (M 12.19, SD 7.38) 
compared to baseline (M 9.54, SD 4.71), p<.001; there was no difference between 
levels of shame after reading information that HPV is very common (M10.03, SD 
6.38) compared to baseline shame, p=1.00; shame was significantly lower after 
reading “common” information when compared to “STI” information, p<.001. See 













Figure 8. Bar graph showing mean internal (Figure 1a) and external (Figure 1b) 
shame scores, as recorded on the modified SSGS, at baseline and following “STI” 
and “common” information. **p<.01;  ***p<.001. 
 
Similarly, there was a significant effect of information on levels of external shame on 
the modified SSGS, F(1.795, 181.282)=9.452, p<.001; df huynh-feldt corrected).  
Shame was significantly higher after reading information that HPV is sexually-




was no difference between levels of shame after reading information that HPV is very 
common (M 8.60, SD 5.55) compared to baseline shame, p=1.00; shame was 
significantly lower after reading “common” information when compared to “STI” 
information, p<.001. See Figure 8b. 
Association between shame and depression, anxiety and wellbeing 
Internal and external shame were associated with higher levels of depression and 
anxiety and were also associated with poorer wellbeing. See Table 9 for full 
correlation matrix. 
Table 9. Correlation matrix of baseline depression, anxiety wellbeing and internal 
and external shame 
HADS=Hospital Anxiety and Depression Inventory; WEMWBS = Warwick 
Edinburgh Mental Wellbeing Scale; SSGS = State Shame and Guilt Scale; MSSGS = 
modified State Shame and Guilt Scale. ***p<.001 
History of depression was associated with differences in baseline levels of internal 
[F(2,106)=10.967, p<.001] and external [F(2,103)=7.082, p=.001] shame. Post hoc 
tests indicated that women with multiple episodes of depression had significantly 
higher internal shame (M 10.93, SD 4.85) than those with a single episode of 
depression (M 7.82, SD 3.62), p=.011, and those with no history of depression (M 
6.12, SD 1.36), p<.001. Post hoc tests indicated that women with multiple episodes of 
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no history of depression (M 5.69, SD 1.54), p=.003; there was no difference with 
women with a single episode of depression (M 7.18, SD 2.42). 
History of anxiety was associated with differences in baseline levels of internal 
[F(2,107)=4.961, p=.009] and external [F(2,104)=3.201, p=.045] shame. When 
comparing between groups, post hoc tests did not indicate significant differences in 
internal shame between women with multiple episodes of anxiety (M 10.30, SD 4.79), 
a single episode (M 7.15, SD 3.31) or no history of anxiety (M 7.21, SD 3.07).  Post 
hoc tests also did not indicate significant differences in internal shame between 
women with multiple episodes of anxiety (M 8.99, SD 4.59), a single episode (M 6.67, 
SD 2.02) or no history of anxiety (M 6.46, SD 2.73). 
Participants rated their mood as significantly lower following “STI” information (M 
4.37, SD 2.53) compared to following “common” information (M 5.20, SD 2.48), 
t(109)=5.516, p<.001. Wellbeing scores were also lower following “STI” information 
(M 4.87, SD 2.54) compared to “common” information (M 5.56, SD 2.50), 
t(109)=4.687, p<.001. Participants reported more anxiety following “STI” 
information (M 5.25, SD 2.86) compared to “common” information (M 4.83, SD 2.71) 
t(109)=-2.293, p=.024. 
Discussion 
The current study provides new findings on HPV-related shame, anxiety and low 
mood in women with cervical cancer, with important implications for the treatment 
and support of patients. 
The results provide the first direct evidence that the sexually-transmitted nature of 
HPV is associated with both internal and external shame in women with cervical 
cancer. Women experienced higher levels of state shame after reading “STI” 
information compared to baseline and after “common” information. Information on 
the high prevalence of HPV was associated with reduced state shame, when compared 
to “STI” information, although did not reduce lower than it was at baseline.  
The results indicate that shame is associated with low mood, anxiety and poor mental 
wellbeing in women with cervical cancer. Participants reported state reductions in 
mood and wellbeing, and increased state anxiety after reading “STI” information. In 
contrast, they experienced improvements in mood and wellbeing and reduced anxiety 
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after reading “common” information. Furthermore, shame was associated with 
symptoms of depression and anxiety at baseline, and women who reported a history 
of repeated episodes of anxiety and depression were at particular risk of experiencing 
high levels of baseline shame. 
While the study was not intended to provide a direct analysis of the model of shame 
outlined in the introduction, the findings can be interpreted to support the theory that 
shame consists of both an internally and externally focused component, occurs in the 
context of cultural stigma and is strongly associated with an emotional response 
(Gilbert, 2006). The findings indicated that both internal and external shame were 
heightened following “STI” information, suggesting a possible association between 
shame and culturally stigmatised sexual permissiveness. The reduced levels of shame 
observed following “common” information possibly reflect a reduction in cultural 
stigma, as HPV is then perceived as the norm, rather than the exception. In addition, 
participants experienced lower mood and increased anxiety following “STI” 
information, providing evidence of the association between shame and a strong 
emotional response (Gilbert, 2006).  
The findings have implications for patients, acknowledging that many women feel 
shame when faced with “STI” information, but that the virus is so common that 
nobody would be justified in judging this negatively. 
At a service level, the findings help clinicians to better understand the emotional 
experiences of patients, not only helping inform how they provide information, but 
also how they support them through the information and treatment process more 
generally. The findings provide some specific suggestions for practice: 
While clinicians should not fear talking about “STI” information, as patients likely 
already know this, they should be aware that information and knowledge about the 
sexual transmission of HPV will likely be associated with increases in shame. 
Clinicians should carefully consider how “STI” information is presented and how 
women are supported with this; it may be beneficial to consistently include 
information about the high prevalence of HPV when discussing it, for example by 
routinely referring to it as a “very common virus”. 
Clinicians may need to generally be vigilant for feelings of shame, for example if a 
patient is using self-critical language that portrays a sense of shame (for example, “I 
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think I’m disgusting”, “people think I’m a slut”), as they might benefit from active 
engagement with supportive services. While some patients might benefit from 
psychological therapy and support [e.g. cognitive behavioural therapy, compassion-
focussed therapy (Gilbert, 2009)], frontline non-psychologically trained staff also 
have a key role in providing empathic and compassionate care. Clinicians can support 
patients to gently challenge these ideas and find more self-compassion, for example 
by exploring evidence against negative thoughts, or exploring how they might respond 
to a friend in the same situation. It is important that clinicians do not invalidate 
patients’ experiences by shutting these conversations down but allow space to talk 
about these difficult thoughts and feelings. Similarly, the results indicate that shame 
is associated with increased risk of depression and anxiety (and vice versa), suggesting 
patients may benefit from opportunities to access formal and informal mental health 
support for low mood and anxiety. 
The results indicate that women with a history of depression and/or anxiety may be at 
particular risk for high levels of shame. Two brief questions were effective at 
identifying this risk: 
Have you ever had a period of time during your life when you were feeling:  
a. depressed or down most of the day, nearly every day? (a) Yes, once (b) 
Yes, more than once (c) No 
b. very anxious or worried most of the day, nearly every day? (a) Yes, 
once (b) Yes, more than once (c) No 
This suggests that, if clinicians are unable to routinely screen for mental health 
problems through lengthier questionnaires, they might ask these two questions at the 
initial appointment to identify at-risk patients who might need active engagement with 
supportive services at the time of diagnosis and beyond. It is important to note that 
these questions cannot replace validated questionnaires, as psychometrics and 
sensitivity/specificity has not been assessed, but they may have value for clinicians 
who don’t have the skills or time to score and interpret full questionnaires, or in 
situations where it does not feel appropriate to ask patients to complete lengthy 
measures.  
When thinking at the wider public-health level, the results of the study suggest that 
patients with cervical cancer may anticipate and expect stigmatising attitudes towards 
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sexual permissiveness. This reflects the recent survey of the general public by the Eve 
Appeal found that one fifth of women associated gynaecological cancers with sexual 
promiscuity and over one third of women believed reducing shame and stigma around 
gynaecological health and sex would enable them to talk more openly about such 
health issues (The Eve Appeal, 2015).This suggests that public health campaigns may 
benefit from targeting stigmatising and shaming attitudes to sexual permissiveness 
and increase awareness of the prevalence of HPV.  
The study has a number of strengths. It is the first study (to the authors’ knowledge) 
that directly explores HPV-related shame, depression and anxiety in women with 
cervical cancer. The study provides strong evidence that “STI” information is 
associated with shame and provides evidence of link between shame and 
depression/anxiety. Methodologically the study was fully powered. However, there 
were limitations that should also be considered. Brief mood ratings were not recorded 
at baseline, meaning the only comparison was between mood following “STI” and 
“common” information. This will have affected interpretation, as it was not possible 
to compare to a stable baseline or establish whether differences reflect worsening of 
mood following “STI” information or improvement following “common” 
information. In addition, the Modified SSGS or the two items indexing history of 
depression and anxiety were not validated measures. These limitations mean the 
findings should be treated as preliminary and requiring further research. Finally, it is 
important to note that the baseline measures of shame, anxiety and depression were 
not directly linked to experiences of cervical cancer, as general measures were used 
without reference to their diagnosis. This means it is not possible to directly link the 
associations between baseline levels of shame, depression and anxiety with 
experiences with cervical cancer, and instead should consider shame, depression and 
anxiety in the context of cervical cancer. The state measures of shame, mood, 
wellbeing and anxiety following each level of information were specific to 
experiences of cervical cancer, however further research should explore the more 
general experiences of shame associated with diagnosis. 
An important future direction for research is to explore factors that might protect 
against shame associated with “STI” information, for example whether information 
that HPV is very common could protect against this shame. Modelling this in an 
experimental setting would require a full cross-over design, which was beyond the 
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scope of the current project, and wording issues, in which STI information was 
presented early, meant we were unable to perform any preliminary analyses with the 
current design. This design would ideally be completed with patients who had no prior 
“STI” or “common” knowledge, however this is unlikely to be feasible, as the current 
study found all participants already knew the “STI” information. This design would 
therefore need to be part of the diagnosis conversations themselves, which might pose 
an ethical challenge. Qualitative research into experiences of HPV-related shame, 
depression and anxiety, for example, exploring how patients found out about the STI 
relationship and how they manage internal and external shame, would also be of 
significant clinical value in understanding how to support patients. 
In conclusion, the current study provides new research on the psychological 
experiences of women with cervical cancer, providing an understanding of HPV-
related shame, depression and anxiety. The results have implications for how to 
support patients who are at risk of experiencing high levels of shame, in particular 
around HPV-information provision, identifying at-risk patients, and psychological 
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Cervical cancer is considered a “preventable” cancer, with close to 100% of cases 
associated with high-risk strains of a common infection, Human Papilloma Virus 
(HPV). The virus is sexually-transmitted through intimate skin-to-skin contact 
(Cancer Research UK, 2016). HPV is very common, and it is estimated that at least 
80% of people will contract the virus at some point in their life. 
Cervical cancer patients are known to be at particular risk of experiencing anxiety, 
depression and other mental health difficulties, even when compared to patients with 
other gynaecological cancers (Bradley, Rose, Lutgendorf, Costanzo, & Anderson, 
2006). There is some preliminary evidence that these difficulties might be associated 
with experiences of shame and stigma around the sexual-transmission of HPV. 
Research has indicated that HPV diagnosis (in the absence of cervical cancer 
diagnosis) is associated with shame, anxiety and distress (Kahn et al., 2007; Maissi et 
al., 2004). A recent survey found that one fifth of women associated gynaecological 
cancers with sexual promiscuity (The Eve Appeal, 2015), and a separate study found 
that patients in a vignette are rated by others as more “dirty”, “dishonest” and 
“unwise”,  and triggering feelings of moral disgust, when HPV is specified as the 
cause (Shepherd & Gerend, 2013). 
Despite this, there has previously been no research exploring how women with 
cervical cancer experience HPV information. The current study investigated whether 
experiences of shame are associated with knowledge of the sexually-transmitted 
nature of HPV. The study explored three main questions: 
1. Is shame in cervical cancer associated with knowledge that HPV is sexually-
transmitted? 
2. Does information that HPV is very common reduce experiences of shame in 
women with cervical cancer? 
3. Is shame associated with increased depression and anxiety in women with 
cervical cancer? 
One hundred and ten women with cervical cancer completed a repeated measures 
study, during which they read information that HPV is (1) considered to be a sexually-
transmitted virus and (2) very common. Participants completed measures of shame, 
mood and anxiety after each level of information.  
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The results indicated that information that HPV is sexually-transmitted is associated 
with experiences of shame: women experienced higher levels of state shame after 
reading “STI” information compared to baseline and after “common” information. 
Information on the high prevalence of HPV was associated with reduced state shame, 
when compared to “STI” information, although did not reduce lower than it was at 
baseline. The results indicate that shame is associated with low mood, anxiety and 
poor mental wellbeing in women with cervical cancer. Participants reported state 
reductions in mood and wellbeing, and increased state anxiety after reading “STI” 
information. In contrast, they experienced improvements in mood and wellbeing and 
reduced anxiety after reading “common” information. Furthermore, shame was 
associated with symptoms of depression and anxiety at baseline, and women who 
reported a history of repeated episodes of anxiety and depression were at particular 
risk of experiencing high levels of baseline shame. 
The findings help clinicians to better understand the emotional experiences of 
patients, not only helping inform how they provide information, but also how they 
support them through the information and treatment process more generally. The 
findings provide some specific suggestions for clinical practice, including: 
• Be aware of the shame associated with HPV. Consider referring to HPV as a 
“very common virus” when discussion the sexual-transmission of the virus 
• Be alert for indications that patients are experiencing feelings of shame – these 
patients might benefit from psychological therapy and/or support 
• Routinely ask about previous experiences of anxiety and depression, as this 
can help identify patients particularly at risk for HPV-related shame 
In conclusion, the current study provides new research on the psychological 
experiences of women with cervical cancer, providing an understanding of HPV-
related shame, depression and anxiety. The results have implications for how to 
support patients who are at risk of experiencing high levels of shame, in particular 
around HPV-information provision, identifying at-risk patients, and psychological 
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Due to having previously completed a PhD in experimental psychology followed by 
a postdoc, I started the DClinPsy with experience in research. I have therefore used 
training to consolidate and develop my research skills in running projects with, and 
about, clinical populations. Throughout the course I have completed three research 
projects: The Main Research Project, the Literature Review/Meta-analysis and the 
Service Improvement Project. I have also completed five case studies, illustrating 
individual piece of work from each of my placements. All these pieces of work have 
helped me to develop skills in clinically relevant research, and they are all pieces of 
work that I am proud of. Perhaps the biggest challenge has been juggling these 
projects all at once. In order to illustrate the research that I have completed, this 
connecting narrative will provide an overview of these pieces of work, as well as 
reflections on my experiences of completing them. 
Main research project 
Study selection and development 
My main research project explored experiences of HPV-related shame, depression 
and anxiety in women with cancer. It is a project that I am particularly proud of, 
particularly as HPV-related shame has never previously been explored in women with 
cervical cancer. I was really engaged with this project throughout my training and 
have submitted it for publication. 
The idea for this project stemmed from the research day that we had early in our first 
year of training. During the day I had a couple of conversations about shame and 
health with Dr Megan Wilkinson-Tough and Dr Cara Davis, who would end up as my 
two supervisors. I took away two ideas focusing on women with cancer – (1) 
experiences of visible and invisible differences (2) feelings of shame. Looking into 
the idea around visible and invisible difference, I noticed that the existing literature 
was extensive and, in some ways, saturated. It felt as if any research would be 
replicating previous findings, and I wanted to do something more original and 
impactful. I wanted to move away from completing research for research’s sake, i.e. 
just finding a project because I needed to for DClinPsy requirements.  
With this in mind, I kept getting drawn to ideas around shame and women’s health. 
From reading around, I became more aware of the association between HPV and 
cervical cancer, and this was something that really struck me. I read the Eve Appeal 
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findings about shame and gynaecological cancer, and also Waller’s paper in which 
they explored shame to hypothetical HPV diagnoses. My previous research has 
included work around risky sexual behaviour, particularly in men who have sex with 
men, and I was very aware of how comparatively more open discussion is about men’s 
sexual experiences, and in many ways the more cultural acceptance there is around 
men having sex. Shame and cervical cancer seemed a natural and exciting avenue of 
research for me to pursue and I was struck by how little research there is available in 
this field, and how important this felt to remedy.  
I was initially drawn to adapting the Waller paper (which I ended up doing) but had 
some concerns about the ethical implications of asking patients about their 
experiences of shame. I went back and forth and back and forth over different research 
designs, before emailing Dr Davis and Dr Wilkinson-Tough some suggestions. We 
ended up meeting, debating the different ideas, before settling on my original idea of 
adapting the Waller paper. To ensure it felt appropriate and relevant, I consulted with 
a woman who had previously had cervical cancer, who gave me some advice around 
wording. 
Ethical approval and recruitment 
Once I had decided on my design, the next step was deciding recruitment strategy, 
which, in term, determined which ethical approval bodies I was required to approach. 
Recruitment was initially a worry as Dr Samantha Cole (my field supervisor) at 
UHBristol was concerned about the likelihood of being able to recruit sufficiently 
from the service. Dr Cole also wondered whether clinicians might be nervous about 
distributing a questionnaire about experiences of shame. At this point I decided that 
online recruitment might be the most successful approach. To reduce the burden of 
ethical approval applications, and to get the project off the ground as quickly as 
possible, I decided to apply for ethics through the university, and recruit online, and 
then only apply for NHS ethics if numbers were too low and I needed to try to find 
more participants through the NHS. However, I quickly realised a flaw with this plan 
– that if I subsequently applied for NHS approval, and was asked to make significant 
changes, that I would end up with two versions of the study (one University approved, 
and the other NHS approved). As such, I decided to apply through both NHS and 
university ethics, and recruit through both the NHS and online simultaneously. To 
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maximise my chances, I also approached Dr Sue Gessler, a clinical psychologist 
working in the field at UCL, who kindly agreed to be involved in the project, and 
recruit through my second NHS site. Around this time Dr Cole went on maternity 
leave, and Dr Jennie Norris kindly supported recruitment at UHBristol. 
Despite my initial worries, recruitment went well, and I met my target, which was a 
huge relief. I was initially hoping for more NHS recruitment (I think I ended up with 
three participants from the two NHS sites in total) but was pleased to have had the 
experience of applying for NHS ethics – it was a useful opportunity to get experience 
of this.  
Data analysis and write up 
I completed data analysis myself, with minimal support from supervisors. I wrote up 
the project with comments on multiple drafts from university supervisors and Dr 
Gessler (Dr Cole was on maternity leave during this time). 
Contributions to clinical practice 
Women with cervical cancer’s experience of HPV information is a poorly understood 
area. The project contributes to our understanding of the impact of this information, 
particularly information on the sexual-transmission of HPV. The project gives several 
recommendations for clinical practice, specifically around how clinicians can best 
support patients through the diagnosis and information process and beyond. Based on 
my findings, future directions for further research were recommended.  
Challenges and personal learning 
I was lucky enough that my main research felt fairly straightforward throughout. As I 
felt so passionate about the project I was motivated to complete it and was excited to 
find our hypotheses were supported. I took learning from it at both a research and 
clinical level. At the research level, I learnt skills in how to run studies with 
participants from a clinical group, with a very limited budget. At a clinical, and 
perhaps personal, level, the project really highlighted to me the psychological and 
emotional impact a diagnosis of cervical cancer. I found myself becoming more and 
more impassioned about the experiences of my participants and I feel that this project 
has extended beyond my research and helped me to become a more aware clinician. 
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Experiences of shame are now at the forefront of my mind in much of my clinical 
work. 
Critical review of the literature 
Study selection 
My critical review was the last of my projects that I developed an idea for. The idea 
was developed in conjunction with Dr Jo Daniels, an expert in the field of Chronic 
Fatigue Syndrome (CFS), as she had identified a gap in the literature. Together we 
initially planned a briefer systematic review, which simply summarised the prevalence 
of anxiety and depression in CFS. With time and discussion, we ended up deciding to 
extend this to include a meta-regression of the impact of anxiety and depression on 
treatment outcomes. This extension made the project feel more clinically relevant and 
felt as if the project would have real value for clinicians and researchers. 
Data analysis 
As I did not have experience in running meta-analyses or meta-regression, I 
approached a couple of different people for support with the analysis. Dr Ian Walker 
gave me some initial advice, however was not able to help further. I then approached 
Adam von Ende, a friend not affiliated with the university, who was able to offer 
support and advice with the data analysis. Mr von Ende is to be included as an author 
on any papers arising from the project.  
Contributions to the literature 
The review highlighted the prevalence of anxiety and depression in CFS and found 
evidence that depressive symptoms may be associated with poorer treatment 
outcomes in physical functioning. These findings have implications for the support 
and care of patients with CFS, suggesting that their emotional and psychological needs 
should be carefully considered as part of their support.  
Challenges and personal learning 
CFS is a complex condition that is poorly understood. As I developed this project, and 
immersed myself more in the literature, I became increasingly aware of the frustration 
many patients feel, and their experiences of feeling misunderstood and criticised by 
health professionals. It is evident that many patients feel very dismissed by clinicians, 
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and this was something I was keen not to do. I was careful in the write up not to 
dismiss experiences or suggest in any way that the condition may be psychological. 
This experience encouraged me to reflect on how a patient might experience my 
research if they were to read it in a journal or article. This is something that I have not 
always considered in the past, instead mostly focusing on how a colleague, academic 
or clinician might experience the work. 
At a skills level, this project enabled me to develop skills in completing a systematic 
review, running meta-analyses and meta-regressions, none of which I had done 
before. The project was challenging and time consuming, but I am ultimately proud 
of it. 
Service Improvement Project 
Study selection and development 
During my working age adults placement in the B&NES Therapies Service, I was 
supervised by Dr Hanna van der Woude. Dr van der Woude was in the process of 
developing the “My Wellbeing Toolkit”, which she planned to introduce to the 
Recovery Service. During my placement we discussed the idea of me completing my 
service improvement project (SIP) on the booklet, to explore experiences of using it. 
Dr Emma Griffith came on board as my course supervisor. 
We initially planned to explore both clinician and client experiences of using the 
booklet, using both quantitative and qualitative methods. However, at the university 
Project Approval Session (PAS), the assessors felt that including both clinicians and 
clients was too large a project and would not be feasible in the time frame. They also 
felt that the initial proposal had not adequately considered that clinicians might not 
have been using the booklet. Based on this, we revised the project to include an 
exploration of usage patterns of the booklet, and Recovery Service clinician 
experiences of the booklet. We decided not to explore client experiences of the 
booklet, as this would have not been feasible if it transpired that clinicians had not 
shared the booklet with them. 
Ethical approval 
Following discussions with the B&NES Research and Development department, the 
project was deemed service-evaluation and not research. I was therefore required to 
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apply for service-evaluation approval from the trust, and ethical approval from the 
University of Bath. 
Process of completing the SIP 
I completed all data collection and analysis myself. The write up was completed with 
comments on drafts from Dr Griffith. 
Challenges and personal learning  
I found the SIP to be my most challenging project for several reasons.  
I had very changeable field supervision on the project. My first supervisor who I 
developed the project in conjunction with, Dr van der Woude, went on maternity leave 
immediately before the Project Approval Session. This meant that she was unable to 
contribute to the changes requested by the panel. Supervision was initially covered by 
Dr Claire Williamson, a senior clinical psychologist in the trust. I met with Dr 
Williamson on a couple of occasions, however she was unable to remain my 
supervisor after her time became more restricted after taking on a more senior role 
within the trust. At this point, my supervision transferred to Dr Chris Gillmore, who I 
met with on a couple of occasions, before Dr van der Woude returned to work. This 
changing supervision on the project felt inconsistent and lacked continuity. Each 
supervisor tried to provide consistency with the previous supervisors, however in 
reality this was difficult to implement. 
Leading on from this, and perhaps affected by the changing supervision, I 
underestimated how difficult it would be to recruit clinicians to the project. I think 
that not being fully engaged with one supervisor in the trust made it difficult to engage 
with the recovery team. As we wanted the team to have had ample opportunity to use 
the booklet, we also had a time restriction in that we had to wait to collect data. This 
meant that I was no longer working in the trust at the time of recruitment/data 
collection. As I had never worked within the Recovery Service, I did not have a 
working relationship with any clinicians within the service. Together these factors 
impacted on recruitment, and I was disappointed that my numbers of returned 
questionnaires were so low. I made multiple attempts to recruit and feel that this effort 
is not reflected in the project output. 
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This project was the first time that I have ever completed qualitative analysis. This 
was a real learning curve for me and took me totally out of my comfort zone. I am 
much more familiar with quantitative analysis and found it challenging to move away 
from this more structured approach. 
Reflecting on the project, I am aware that I found it difficult to meet the needs of the 
specific service, whilst also completing a project that had meaning beyond the scope 
of the particular team and resource. As the focus group schedule and questionnaire 
were specific to the particular resource, the questions were inherently constrained to 
the service. It may have been useful to have a wider focus, thinking about mind-map 
based resources more generally, and this might have resulted in more generalisable 
findings. At the same time, the service requested that the project was specific to the 
particular resource, and it was hard to balance these conflicting needs. When 
considering how I would take a similar project forward in the future, I would aim to 
spend more time in the planning stage considering how I could meet both the needs 
of the service and contribute more generalisable findings.  
Contributions to clinical practice 
Brief interventions that do not sacrifice clinical effectiveness are a burgeoning area of 
research. This project provides preliminary evidence that mind-map based booklets 
are experienced as useful by clinicians, when working in secondary care mental 
health. The project identified that there are, however, barriers to use that need to be 
addressed. Based on these findings, and to ensure clinical utility, we recommend that 
a future project explores client experiences of using the booklet. 
Case studies 
I found writing case studies one of the more challenging aspects of placement, but 
they also helped me to develop important clinical skills.  
My case studies required me to carefully consider my clinical practice, both alongside 
and following my sessions. A key aspect of writing a case study is clarifying the 
theory-practice links – the process helped me to focus on these, and not just plough 
on without considering theory and the literature. Another key component was 
completing regular outcome measures. This experience helped me to consider the 
      89 
importance of routine evaluation and gave me experience of using measures outside 
of a research environment. 
My case studies have varied considerably, in terms of client and content. The vast 
majority of my cases throughout training were complex – it would have been nice to 
have had some more “straightforward” IAPT clients, in which outcome measures and 
treatment protocols were provided to me. The complexity meant that at times I found 
it difficult to put my work into a structured and organised case study and would spend 
days and weeks trying to do so. I am pleased with the case studies that I have 
produced, however would have appreciated more space to complete reflective case 
studies, which did not need to be so structured. I had some interesting cases and 
dilemmas throughout training, that I would have liked to have been able to write about. 
Anticipated post-qualification research 
As I commented at the beginning of this narrative, one of the biggest challenges of 
training has been completing three pieces of research/service improvement, alongside 
my case studies (and consultation project, which hasn’t been mentioned in this 
narrative). Juggling all three projects – holding them in mind, recruiting, running the 
analysis, reading 1000+ abstracts for my critical review, etc – has at times felt 
overwhelming and unmanageable. Despite this, I have managed it. The learning I have 
taken from this experience has been enormous. I have learnt how to complete 
clinically relevant research, and I think that I am a far better researcher for it. 
I am keen to continue to expand my research experience throughout my career as a 
clinical psychologist. This training has given me the skills to manage research 
alongside direct clinical work and has also given me the tools to complete research 
that can have an impact on clinical practice. One of my frustrations with my previous 
academic research experience was the lack of clinical impact, and it has been a real 
pleasure to no longer feel this frustration.  
My ambition is to continue with research in the field of clinical health. I anticipate 
that conducting research alongside clinical work will not always be easy. I can 
imagine that a busy workload and other service-related pressures will be a major 
barrier to completing further research. I hope that I can partly address this by 
continuing with links at the university, and hopefully agreeing some research time 
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into a job plan. I plan to find out whether it would be possible to supervise a future 
bath trainee on their own research project. 
In conclusion, my research projects have been challenging, but ultimately greatly 
rewarding. I am immensely proud of the work I have completed, and hope that you, 
the reader, feel that this is justified.  
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Appendix A – BMJ Instructions for authors 
 
Research 
We have produced a checklist to help authors decide whether The BMJ is the right journal 
for their research. If the work does not seem to fit in The BMJ, it may be better sent straight 
to another journal with a more specialist or local readership or a higher acceptance rate. 
To learn more about the kind of research articles we give priority to, and what services we 
offer to authors of research, please read the editorial "Publishing your research study in 
the BMJ?". Please note that we welcome studies - even with "negative" results - as long as 
their research questions are important, new, and relevant to general readers and their designs 
are appropriate and robust. 
Word count and style 
To encourage full and transparent reporting of research we do not set fixed word count 
limits for research articles. Nonetheless, we ask you to make your article concise and make 
every word count. You will be prompted to provide the word count for the main text 
(excluding the abstract, references, tables, boxes, or figures) when you submit your 
manuscript. 
Original research articles should follow the IMRaD style (introduction, methods, results, 
and discussion) and should include a structured abstract (see below), a structured discussion, 
and a succinct introduction that focuses - in no more than three paragraphs - on the 
background to the research question. 
For an intervention study, the manuscript should include enough information about the 
intervention(s) and comparator(s) (even if this was usual care) for reviewers and readers to 
understand fully what happened in the study. To enable readers to replicate your work or 
implement the interventions in their own practice, please also provide any relevant detailed 
descriptions and materials (uploaded as one or more supplemental files, including video and 
audio files where appropriate). Alternatively, please provide in the manuscript URLs to 
openly accessible websites where these materials can be found. 
Please ensure that the discussion section of your article comprises no more than a page and a 
half and follows this overall structure, although you do not need to signpost these elements 
with subheadings: 
• Statement of principal findings 
• Strengths and weaknesses of the study 
• Strengths and weaknesses in relation to other studies, discussing important differences in 
results 
• Meaning of the study: possible explanations and implications for clinicians and 
policymakers 
• Unanswered questions and future research 
This video gives more detailed advice on writing each section of a research paper for The 
BMJ. 
Structured abstract 
Please ensure that the structured abstract is as complete, accurate, and clear as possible and 
has been approved by all authors. We may screen original research articles by reading only 
the abstract. 
Abstracts should be 250- 300 words long: you may need up to 400 words, however, for a 
CONSORT or PRISMA style abstract. MEDLINE can now handle up to 600 words. 
Abstracts should include the following headings, but they may be modified for abstracts of 
clinical trials or systematic reviews and meta-analyses according to the requirements on 
the the CONSORT extension for abstracts and the PRISMA extension for abstracts, 
respectively. 
• Objectives - a clear statement of the main aim of the study and the major hypothesis tested 
or research question posed 
• Design - including factors such as prospective, randomisation, blinding, placebo control, 
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case control, crossover, criterion standards for diagnostic tests, etc. 
• Setting - include the level of care, eg primary, secondary; number of participating centres. 
Be general rather than give the name of the specific centre, but give the geographical 
location if this is important 
• Participants (instead of patients or subjects) - numbers entering and completing the 
study, sex, and ethnic group if appropriate. Give clear definitions of how selected, entry and 
exclusion criteria. 
• Interventions - what, how, when and for how long. This heading can be deleted if there 
were no interventions but should normally be included for randomised controlled trials, 
crossover trials, and before and after studies. 
• Main outcome measures - those planned in the protocol, those finally measured (if 
different, explain why). 
• Results - main results with (for quantitative studies) 95% confidence intervals and, where 
appropriate, the exact level of statistical significance and the number need to treat/harm. 
Whenever possible, state absolute rather than relative risks. 
• Conclusions - primary conclusions and their implications, suggesting areas for further 
research if appropriate. Do not go beyond the data in the article. Conclusions are important 
because this is often the only part that readers look at. 
• Trial registration - registry and number (for clinical trials and, if available, for 
observational studies and systematic reviews). 
When writing your abstract, use the active voice but avoid "we did" or "we found". 
Numbers over 10 do not need spelling out at the start of sentences. p-values should always 
be accompanied by supporting data, and denominators should be given for percentages. 
Confidence intervals should be written in the format (15 to 27) within parentheses, using the 
word "to" rather than a hyphen. Abstracts do not need references. 
Statistical issues 
We want your piece to be easy to read but also as scientifically accurate as possible. We 
encourage authors to review the "Statistical Analyses and Methods in the Published 
Literature or The SAMPL Guidelines" while preparing their manuscript. 
Whenever possible, state absolute rather than relative risks. Please include in the results 
section of your structured abstract (and in the article's results section) the following terms, 
as appropriate: 
For a clinical trial: 
• Absolute event rates among experimental and control groups. 
• RRR (relative risk reduction). 
• NNT or NNH (number needed to treat or harm) and its 95% confidence interval (or, if the 
trial is of a public health intervention, number helped per 1000 or 100,000). 
For a cohort study: 
• Absolute event rates over time (eg 10 years) among exposed and non-exposed groups 
• RRR (relative risk reduction) 
For a case control study: 
• OR (odds ratio) for strength of association between exposure and outcome 
For a study of a diagnostic test: 
• Sensitivity and specificity 
• PPV and NPV (positive and negative predictive values) 
The box stating 'what is known' and 'what this study adds' should also reflect accurately the 
above information. Under what this study adds, please give the one most useful summary 
statistic eg NNT. 
Please do not use the term 'negative' to describe studies that have not found statistically 
significant differences, perhaps because they were too small. There will always be some 
uncertainty, and we hope you will be as explicit as possible in reporting what you have 
found in your study. Using wording such as "our results are compatible with a decrease of 
this much or an increase of this much" or 'this study found no effect' is more accurate and 
helpful to readers than "there was no effect/no difference." Please use such wording 
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throughout the article, including the structured abstract and the box stating what the paper 
adds. 
Provide one or more references for the statistical package(s) used to analyse the data - for 
example, RevMan for a systematic review. There is no need to provide a formal reference 
for a very widely used package that will be familiar to general readers - for example, Stata - 
but please say in the text which version you used. 
Reporting guidelines 
Reporting guidelines promote clear reporting of methods and results to allow critical 
appraisal of the manuscript. We ask that all manuscripts be written in accordance with the 
appropriate reporting guideline. Please submit as supplemental material the appropriate 
reporting guideline checklist showing on which page of your manuscript each checklist item 
appears. A complete list of guidelines can be found in the website of the Equator Network. 
Below is the list of most often used checklists but others may apply. 
For a clinical trials, use the CONSORT checklist and also include a structured abstract that 
follows the CONSORT extension for abstract checklist, the CONSORT flowchart and, 
where applicable, the appropriate CONSORT extension statements (for example, for cluster 
RCTs, pragmatic trials, etc.). A completed TIDieR checklist is also helpful as this helps to 
ensure that trial interventions are fully described in ways that are reproducible, usable by 
other clinicians, and clear enough for systematic reviewers and guideline writers. 
For systematic reviews or meta-analysis of randomised trials and other evaluation studies, 
use the PRISMAchecklist and flowchart and use the PRISMA structured abstract checklist 
when writing the structured abstract. 
For studies of diagnostic accuracy, use the STARD checklist and flowchart. 
For observational studies, use the STROBE checklist and any appropriate extension 
STROBE extensions. 
For genetic risk prediction studies, use GRIPS. 
For economic evaluation studies, use CHEERS. 
For studies developing, validating or updating a prediction model, use TRIPOD. 
For articles that include explicit statements of the quality of evidence and strength of 
recommendations, we prefer reporting using the GRADE system. 
Cover letter 
A cover letter is your opportunity to introduce your study to the editor, highlighting the 
most important findings and novelty. Please also include in the letter the following 
information: 
• Details of previous publications from the same study - including in scientific abstracts or 
partial reports by the media at scientific meetings and in foreign language journals. 
• Details of any previous publication of the same study in electronic form, including on any 
preprint server. For example, The BMJ does not consider posting of protocols and results in 
clinical trials registries to be prior publication, but we would like to know if results have 
been posted, and where (please provide URLs or trial registration details). And we are 
pleased to consider articles based on longer systematic reviews and meta-analyses published 
at the Cochrane Library or HTA database. 
• In most cases, we will follow suggestions for preferred and non-preferred reviewers. If you 
have suggestions for preferred reviewers, please provide us with their names and contact 
details; we may invite some of them to review the paper. Please also let us know if you 
would not like us to invite specific reviewers to look at your work but provide an 
explanation for your request. 
• Assurance that a study funded or sponsored by industry follows the guidelines on good 
publication practice.These GPP2 guidelines aim to ensure that such studies are published in 
a responsible and ethical manner. The guidelines cover companies’ responsibility to 
endeavour to publish results of all studies, companies’ relations with investigators, measures 
to prevent redundant or premature publication, the roles of authors and contributors, and the 
role of professional medical writers. 
• Assurance that any article written by a professional medical writer follows the guidelines 
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by the European Medical Writers' Association on the role of professional medical writers. 
The guidelines emphasise the importance of respecting widely recognised authorship 
criteria, and in particular of ensuring that all people listed as named authors have full control 
of the content of articles. The role of professional medical writers must be transparent. 
Please name any professional medical writer among the list of contributors to any article 
for The BMJ (not only original research articles), and specify in the formal funding 
statement for the article who paid the writer. Writers and authors must have access to 
relevant data while writing articles. Medical writers have professional responsibilities to 
ensure that the articles they write are scientifically valid and are written in accordance with 
generally accepted ethical standards. 
Mandatory patient and public involvement reporting 
The BMJ is encouraging active patient and public involvement in clinical research as part of 
its patient partnership strategy. This is research which is "co produced" with patients, carers, 
or members of the public. Patient involvement in this context is not about being a research 
participant, answering surveys, or being an interviewee. It encompasses setting research 
priorities, defining research questions and outcome measures, providing input into study 
design and conduct, dissemination, or results and evaluation. 
To support co production of research we request that authors provide a Patient and Public 
Involvementstatement in the methods section of their papers. We request this to both 
encourage the movement and ensure that BMJ readers can easily see whether, and if so how, 
patients and the public were involved in the research. If they were not involved in any way 
this information should be formally documented in the Patient and Public Involvement 
statement. 
As co production of research with patients and the public is relatively new we appreciate 
that not all authors will have involved them in their studies. We also appreciate that 
patient/public involvement may not be feasible or appropriate for all papers. We therefore 
continue to consider papers where they were not involved. 
 
The Patient and Public Involvement statement should provide a brief response to the 
following questions, tailored as appropriate for the study design reported: 
At what stage in the research process were patients/public first involved in the research and 
how? 
• How were the research question(s) and outcome measures developed and informed by 
their priorities, experience, and preferences? 
• How were patients/public involved in the design of this study? 
• How were they involved in the recruitment to and conduct of the study? 
• Were they asked to assess the burden of the intervention and time required to participate in 
the research? 
In addition to considering the points above we advise authors to look at guidance for best 
reporting of patient and public involvement as set out in the GRIPP2 reporting checklist.   
Even if patients were not involved in the study described, we suggest that you consider 
enlisting their help in disseminating the research findings. 
 
If information detailing whether there was patient and public involvement, or 
not, is missing in the submitted manuscript we will request authors to provide it. 
 
Where they have been involved we consider it good practice for authors to name and thank 
them in the contributorship statement after seeking their permission to do so; and to clearly 
identify them as patient/public contributors. When they have contributed substantially and 
meet authorship criteria they should be invited to coauthor the manuscript. 
Please note also note that it's The BMJ policy to send relevant research papers for review by 
patient reviewersalongside academic peer reviewers. 
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Links to selected examples of Patient and Public Involvement statements in published 
BMJ research papers showing patient and carer involvement at various stages of the 
research process. 
Comparison of the two most commonly used treatments for pyoderma gangrenosum: results 
of the STOP GAP randomised controlled trial 
Evidence based community mobilization for dengue prevention in Nicaragua and Mexico 
Computerised cognitive behaviour therapy (cCBT) as treatment for depression in primary 
care (REEACT trial): large scale pragmatic randomised controlled trial. 
Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: 
observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer 
and Effectiveness Research (PROSPER) study. 
Example PPI statements to adapt for use in a paper 
Examples to guide the wording for PPI statements 
Data sharing 
We require a data sharing statement for all research papers. For papers that do not 
report a trial, we do not require that the authors agree to share the data, just that they 
say whether they will. 
For reports of clinical trials, we ask that the authors commit to making the relevant 
anonymised patient level data available on reasonable request (see editorial). This policy 
applies to any research article that reports the main endpoints of a randomised controlled 
trial of one or more drugs or medical devices in current use, whether or not the trial was 
funded by industry. 
"Relevant data" encompasses all anonymised data on individual patients on which the 
analysis, results, and conclusions reported in the paper are based. As for "reasonable 
request," The BMJ is not in a position to adjudicate, but we will expect requesters to submit 
a protocol for their re-analysis to the authors and to commit to making their results public. 
We will encourage those requesting data to send a rapid response to thebmj.com, describing 
what they are looking for. If the request is refused we will ask the authors of the paper to 
explain why. 
In addition, we will follow the new ICMJE data sharing policy that goes into place on July 
1, 2018 (see editorial): manuscripts submitted to ICMJE journals that report the results of 
clinical trials must contain a data sharing statement that indicates whether individual de-
identified participant data (including data dictionaries) will be shared; what data in 
particular will be shared; whether additional, related documents will be available (study 
protocol, statistical analysis plan, etc); when the data will become available and for how 
long; by what access criteria data will be shared (including with whom, for what types of 
analyses, and by what mechanism). Clinical trials that begin enrolling participants on or 
after January 1, 2019 must also include a data sharing plan in the trial’s registration. If the 
data sharing plan changes after registration this should be reflected in the statement 
submitted and published with the manuscript, and updated in the registry record. 
We encourage authors of all research articles in The BMJ to link their articles to the raw 
data from their studies. For clinical trials, we require data sharing on request as a minimum 
and- if authors of such trials are willing to go further and share the data openly, so much the 
better. The BMJ has partnered with the Dryad digital repository datadryad.org to make open 
deposition easy and to allow direct linkage by doi from the dataset to The BMJ's article and 
back (for The BMJ's articles' datasets see here). 
Data requesters should do the following: 
• Submit a rapid response to the paper and email the corresponding author for the paper to 
request the relevant data. 
• Be prepared to provide the authors of the paper a detailed protocol for your proposed 
study, and to supply information about the funding and resources you have to carry out the 
study. 
• If appropriate, invite the original author[s] to participate in the re-analysis. 
• If a month elapses without a response from the authors, please email the head of research 
for The BMJ (presently eloder@bmj.com) and cc papersadmin@bmj.com. 
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• The BMJ will assess the request and if appropriate we will encourage the authors or their 
institution to share the data, although we are not in a position to compel data release or 
broker agreements. Our role is limited to making the request process public, and all 
correspondence related to the request may be made public through rapid responses to the 
paper. 
Statements that must be included in Research submissions (Ethics approval, 
funding, and tranparency) 
Ethics approval 
All research studies published in The BMJ should be morally acceptable, and must follow 
the World Medical Association's Declaration of Helsinki. To ensure this, we aim to appraise 
the ethical aspects of any submitted work that involves human participants, whatever 
descriptive label is given to that work including research, audit, and sometimes debate. This 
policy also applies on the very rare occasions that we publish work done with animal 
participants. The manuscript must include a statement that the study obtained ethics 
approval (or a statement that it was not required), including the name of the ethics 
committee(s) or institutional review board(s), the number/ID of the approval(s), and a 
statement that participants gave informed consent before taking part. 
Transparency statement 
Please include in your manuscript a transparency declaration: a statement that the lead 
author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and 
transparent account of the study being reported; that no important aspects of the study have 
been omitted; and that any discrepancies from the study as originally planned (and, if 
relevant, registered) have been explained. 
The BMJ is committed to making the editorial process transparent and ethical. The BMJ’s 
transparency policies are accessible from this link. 
Role of the funding source 
Please include in the manuscript a statement giving the details of all sources of funding for 
the study. As appropriate, the statement must include a description of the role of the study 
sponsor(s) or funder(s), if any, in the study design; in the collection, analysis, and 
interpretation of data; in the writing of the report; and in the decision to submit the article 
for publication. In addition, the statement must confirm the independence of researchers 
from funders and that all authors, external and internal, had full access to all of the data 
(including statistical reports and tables) in the study and can take responsibility for the 
integrity of the data and the accuracy of the data analysis is also required. 
If you are submitting an original article reporting an industry sponsored clinical trial, 
postmarketing study, or other observational study please follow the guidelines on good 
publication practice (GPP2) and on properly reporting the role of professional medical 
writers. Another resource, the Authors' Submission Toolkit: A practical guide to getting 
your research published summarises general tips and best practices to increase awareness of 
journals' editorial requirements, how to choose the right journal, submission processes, 
publication ethics, peer review, and effective communication with editors - much of which 
has traditionally been seen as mysterious to authors. 
The BMJ will not consider for publication any study that is partly or wholly funded by the 
tobacco industry, as explained in this editorial. 
Patient and Public Involvement statement 
Within the Methods section of your paper, please state if and how patients and the public 
were involved in the research you are describing. For more information, please see the 
specific guidance on mandatory reporting of patient and public involvement above. If 
patients and the public were not involved this information should be formally documented 
in the Patient and Public Involvement statement. 
Summary boxes 
Please produce a box offering a thumbnail sketch of what your article adds to the literature. 
The box should be divided into two short sections, each with 1-3 short sentences. 
Section 1: What is already known on this topic 
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In two or three single sentence bullet points, please summarise the state of scientific 
knowledge on this topicbefore you did your study, and why this study needed to be done. Be 
clear and specific, not vague. 
Section 2: What this study adds 
In one or two single sentence bullet points, give a simple answer to the question “What do 
we now know as a result of this study that we did not know before?” Be brief, succinct, 
specific, and accurate. For example: "Our study suggests that tea drinking has no overall 
benefit in depression." You might use the last sentence to summarise any implications for 
practice, research, policy, or public health. For example, your study might have asked and 
answered a new question (one whose relevance has only recently become clear); 
contradicted a belief, dogma, or previous evidence provided a new perspective on something 
that is already known in general; or provided evidence of higher methodological quality for 






Appendix B –Full search terms 
Pubmed: 
("chronic fatigue syndrome" OR “chronic fatigue disorder” OR "myalgic 
encephalomyelitis" OR “myalgic encephalopathy” OR “CFS” OR “CFS/ME” OR 
“ME/CFS”) AND (“Cognitive behavioural therapy” OR “cognitive therapy” OR 
“cognitive behavioral therapy” OR “behavioural therapy” OR “behavioral therapy” 
OR “graded exercise therapy” OR “exercise therapy” OR “exercise” OR “activity” 
OR “activity management” OR “cognitive behaviour therapy” OR “cognitive 
behavior therapy” OR “behaviour therapy” OR “behavior therapy”) AND 
(randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] 
OR placebo[tiab] OR drug therapy[sh] OR randomly[tiab] OR trial[tiab] OR 
groups[tiab] NOT (animals [mh] NOT humans [mh]))  
 
PsycINFO: 
("chronic fatigue syndrome" OR “chronic fatigue disorder” OR "myalgic 
encephalomyelitis" OR “myalgic encephalopathy” OR “CFS” OR “CFS/ME” OR 
“ME/CFS”)  AND (“Cognitive behavioural therapy” OR “cognitive therapy” OR 
“cognitive behavioral therapy” OR “behavioural therapy” OR “behavioral therapy” 
OR “graded exercise therapy” OR “exercise therapy” OR “exercise” OR “activity” 
OR “activity management” OR “cognitive behaviour therapy” OR “cognitive 
behavior therapy” OR “behaviour therapy” OR “behavior therapy”) AND (random* 




("chronic fatigue syndrome" OR “chronic fatigue disorder” OR "myalgic 
encephalomyelitis" OR “myalgic encephalopathy” OR “CFS” OR “CFS/ME” OR 
“ME/CFS”)  AND (“Cognitive behavioural therapy” OR “cognitive therapy” OR 
“cognitive behavioral therapy” OR “behavioural therapy” OR “behavioral therapy” 
OR “graded exercise therapy” OR “exercise therapy” OR “exercise” OR “activity” 
OR “activity management” OR “cognitive behaviour therapy” OR “cognitive 
behavior therapy” OR “behaviour therapy” OR “behavior therapy”) AND ('crossover 
procedure':de OR 'double-blind procedure':de OR 'randomized controlled trial':de 
OR  'single-blind procedure':de OR (random* OR  factorial* OR crossover* OR cross 
NEXT/1 over* OR placebo* OR doubl* NEAR/1 blind* OR singl* NEAR/1 blind* OR 
assign* OR allocat* OR volunteer*):de,ab,ti) 
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Appendix C –List of authors contacted 
Reference Action Outcome 
Broadbent 
2016 & 2017 
Emailed to request any available anxiety 
and/or depression data 
No response; paper 
excluded 
Deale 1997 Emailed to confirm lower age range of 
participants.  
Emailed to request any available anxiety 
data. 
No response; paper 
included (no anxiety data 
available) 
Deale 2001 Emailed to request any available anxiety 
and/or depression data 
No response; paper 
excluded 
Fulcher 1997 Emailed to confirm age range of 
included participants 
No response; paper 
included 
Lattie 2016 Emailed to request anxiety and/or 
depression data for their different 
groups 
No response; paper 
excluded 
Nunez 2011 Emailed to confirm age range of 
included participants 
Author responded 
confirming adult sample; 
paper excluded as 
combination therapy 
Prins 2001 Emailed to ask if a specific measure of 
anxiety/depression was recorded (they 
refer to  generic SCL-90 questionnaire 
in text) 
No response; paper 
excluded 
Sharpe 2015 Emailed to request any available anxiety 
and/or depression data corresponding to 
long-term follow-up sample 




Emailed authors to establish whether 
they consider intervention CBT 






Emailed to request anxiety and/or 
depression data for their different 
groups 
No response; paper 
excluded 
Wiborg 2015 Emailed to ask if a specific measure of 
anxiety/depression was recorded (they 
refer to  generic SCL-90 questionnaire 
in text) 
No response; paper 
excluded 
Knoop 2008 Emailed to request anxiety and/or 
depression data for their different 
groups 
No response; paper 
excluded 
Sharpe 1996 Emailed to ask for additional data from 
paper 
Author responded stating 
data is unavailable 
Wearden 1998 Emailed to ask for additional data from 
paper 
No response 
Researcher Action Outcome 
Prof. Michael 
Sharpe 
Contacted author to request any 
unpublished data 




Contacted author to request any 
unpublished data 





Contacted author to request any 
unpublished data 




Attempted to contact author to request 
any unpublished data 
No email address available 
Dr. Hazel 
O'Dowd  
Contacted author to request any 
unpublished data 




Contacted author to request any 
unpublished data 
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Appendix D –List of borderline papers resolved through discussion 
Papers reporting general measure of psychological wellbeing/distress, but not 
a specific measure of anxiety/depression: 
Prins 2001 Paper reports SCL-90 
Vos-Vromans 2016 Paper reports SCL-90 
Wiborg 2015 Paper reports SCL-90 
Lopez 2011 Paper reports POMS total mood disturbance 
Tummers 2012 Paper reports brief symptom inventory 
Papers that include components of CBT but not full intervention: 
Friedberg 2016 Intervention applies components of CBT but not full 
protocol 
Rimes 2013  Mindfulness based CBT intervention 
Surawy 2005 Mindfulness based CBT intervention 
Thomas 2006 Multiconvergent combination treatment including 
aspects of CBT/GET/others 
Thomas 2008 Multiconvergent combination treatment including 
aspects of CBT/GET/others 
Wearden 2010  Pragmatic rehabilitation with aspects of CBT 
Nunez 2011 Combination treatment 
No suitable control condition: 
Burgess 2012  Face-to-face compared to telephone CBT 




Participants with certain comorbid physical health 
conditions (e.g. mitral valve prolapse and 
hypoglycaemia) were not excluded 
Vos-Vromans 2016b Secondary analysis of data; excluded because paper did 




Appendix E – Literature review, data extraction form 
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Appendix F – Journal of mental health: Instructions for authors  
Thank you for choosing to submit your paper to us. These instructions will ensure 
we have everything required so your paper can move through peer review, 
production and publication smoothly. Please take the time to read and follow them 
as closely as possible, as doing so will ensure your paper matches the journal's 
requirements. For general guidance on the publication process at Taylor & Francis 
please visit our Author Services website.  
 
This journal uses ScholarOne Manuscripts (previously Manuscript Central) to peer 
review manuscript submissions. Please read the guide for ScholarOne authors before 
making a submission. Complete guidelines for preparing and submitting your 
manuscript to this journal are provided below.  
 
ABOUT THE JOURNAL 
Journal of Mental Health is an international, peer-reviewed journal publishing high-
quality, original research. Please see the journal's Aims & Scope for information 
about its focus and peer-review policy. 
Please note that this journal only publishes manuscripts in English. 
Journal of Mental Health accepts the following types of article: Original Article, 
Review Article, Research and Evaluation, Book Review and Web Review. 
Book Reviews  
All books for reviewing should be sent directly to Martin Guha, Book Reviews 
Editor, Information Services & Systems, Institute of Psychiatry, KCL, De Crespigny 
Park, PO Box 18, London, SE5 8AF 
 
CONTENTS 
Taylor & Francis is committed to peer-review integrity and upholding the highest 
standards of review. Once your paper has been assessed for suitability by the editor, 
it will then be double blind peer reviewed by independent, anonymous expert 
referees. Find out more about what to expect during peer review and read our 
guidance on publishing ethics. 
 
PREPARING YOUR PAPER 
Structure 
Your paper should be compiled in the following order: title page; abstract; 
keywords; main text introduction, materials and methods, results, discussion; 
acknowledgments; declaration of interest statement; references; appendices (as 
appropriate); table(s) with caption(s) (on individual pages); figures; figure captions 
(as a list). 
Word Limits 
Please include a word count for your paper. 
The total word count for Review Articles should be no more than 6000 words. All 
other articles should be no more than a total of 4000 words. We do not include the 
abstract, tables and references in this word count. Manuscripts are limited to a 
maximum of 4 tables and 2 figures. 
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Style Guidelines 
Please refer to these quick style guidelines when preparing your paper, rather than 
any published articles or a sample copy. 
Any spelling style is acceptable so long as it is consistent within the manuscript. 
Please use double quotation marks, except where “a quotation is ‘within’ a 
quotation”. Please note that long quotations should be indented without quotation 
marks. 
Formatting and Templates 
Papers may be submitted in Word format. Figures should be saved separately from 
the text. To assist you in preparing your paper, we provide formatting template(s). 
Word templates are available for this journal. Please save the template to your hard 
drive, ready for use. 
If you are not able to use the template via the links (or if you have any other 
template queries) please contact authortemplate@tandf.co.uk. 
References 
Please use this reference guide when preparing your paper. 
Checklist: What to Include 
1. Author details. Please include all authors’ full names, affiliations, postal addresses, 
telephone numbers and email addresses on the cover page. Where available, please 
also include ORCiDs and social media handles (Facebook, Twitter or LinkedIn). 
One author will need to be identified as the corresponding author, with their email 
address normally displayed in the article PDF (depending on the journal) and the 
online article. Authors’ affiliations are the affiliations where the research was 
conducted. If any of the named co-authors moves affiliation during the peer-review 
process, the new affiliation can be given as a footnote. Please note that no changes 
to affiliation can be made after your paper is accepted. Read more on authorship. 
2. A structured abstract of no more than 200 words. Use the following headings: 
Background, Aims, Method, Results, Conclusions, Declaration of interest. The 
declaration of interest should acknowledge all financial support and any financial 
relationship that may pose a conflict of interest. Acknowledgement of individuals 
should be confined to those who contributed to the article's intellectual or technical 
content. Read tips on writing your abstract. 
3. You can opt to include a video abstract with your article. Find out how these can 
help your work reach a wider audience, and what to think about when filming. 
4. Between 3 and 8 keywords. Read making your article more discoverable, including 
information on choosing a title and search engine optimization. 
5. Funding details. Please supply all details required by your funding and grant-
awarding bodies as follows:  
For single agency grants  
This work was supported by the [Funding Agency] under Grant [number xxxx].  
For multiple agency grants  
This work was supported by the [Funding Agency #1] under Grant [number xxxx]; 
[Funding Agency #2] under Grant [number xxxx]; and [Funding Agency #3] under 
Grant [number xxxx]. 
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6. Disclosure statement. This is to acknowledge any financial interest or benefit that 
has arisen from the direct applications of your research. Further guidance on what is 
a conflict of interest and how to disclose it. 
7. Data availability statement. If there is a data set associated with the paper, please 
provide information about where the data supporting the results or analyses 
presented in the paper can be found. Where applicable, this should include the 
hyperlink, DOI or other persistent identifier associated with the data 
set(s). Templates are also available to support authors. 
8. Data deposition. If you choose to share or make the data underlying the study open, 
please deposit your data in a recognized data repository prior to or at the time of 
submission. You will be asked to provide the DOI, pre-reserved DOI, or other 
persistent identifier for the data set. 
9. Supplemental online material. Supplemental material can be a video, dataset, 
fileset, sound file or anything which supports (and is pertinent to) your paper. We 
publish supplemental material online via Figshare. Find out more 
about supplemental material and how to submit it with your article. 
10. Figures. Figures should be high quality (1200 dpi for line art, 600 dpi for grayscale 
and 300 dpi for colour, at the correct size). Figures should be supplied in one of our 
preferred file formats: EPS, PS, JPEG, GIF, or Microsoft Word (DOC or DOCX). 
For information relating to other file types, please consult our Submission of 
electronic artworkdocument. 
11. Tables. Tables should present new information rather than duplicating what is in the 
text. Readers should be able to interpret the table without reference to the text. 
Please supply editable files. 
12. Equations. If you are submitting your manuscript as a Word document, please 
ensure that equations are editable. More information about mathematical symbols 
and equations. 
13. Units. Please use SI units (non-italicized). 
 
USING THIRD-PARTY MATERIAL IN YOUR PAPER 
You must obtain the necessary permission to reuse third-party material in your 
article. The use of short extracts of text and some other types of material is usually 
permitted, on a limited basis, for the purposes of criticism and review without 
securing formal permission. If you wish to include any material in your paper for 
which you do not hold copyright, and which is not covered by this informal 
agreement, you will need to obtain written permission from the copyright owner 
prior to submission. More information on requesting permission to reproduce 
work(s) under copyright. 
 
SUBMITTING YOUR PAPER 
1. When submitting an Original Article or Research and Evaluation, please include a 
sentence to confirm that ethical approval has been granted (with the name of the 
committee and the reference number) and that participants have given consent for 
their data to be used in the research. 
2. When submitting a Review, please confirm that your manuscript is a systematic 
review and include a statement that researchers have followed the PRISMA 
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guidance. Please also confirm whether the review protocol has been published on 
Prospero and provide a date of registration. 
This journal uses ScholarOne Manuscripts to manage the peer-review process. If 
you haven't submitted a paper to this journal before, you will need to create an 
account in ScholarOne. Please read the guidelines above and then submit your paper 
in the relevant Author Centre, where you will find user guides and a helpdesk. 
Please note that Journal of Mental Health uses Crossref™ to screen papers for 
unoriginal material. By submitting your paper to Journal of Mental Health you are 
agreeing to originality checks during the peer-review and production processes. 
On acceptance, we recommend that you keep a copy of your Accepted Manuscript. 
Find out more about sharing your work. 
 
DATA SHARING POLICY 
This journal applies the Taylor & Francis Basic Data Sharing Policy. Authors are 
encouraged to share or make open the data supporting the results or analyses 
presented in their paper where this does not violate the protection of human subjects 
or other valid privacy or security concerns. 
Authors are encouraged to deposit the dataset(s) in a recognized data repository that 
can mint a persistent digital identifier, preferably a digital object identifier (DOI) 
and recognizes a long-term preservation plan. If you are uncertain about where to 
deposit your data, please see this information regarding repositories. 
Authors are further encouraged to cite any data sets referenced in the article and 
provide a Data Availability Statement. 
At the point of submission, you will be asked if there is a data set associated with the 
paper. If you reply yes, you will be asked to provide the DOI, pre-registered DOI, 
hyperlink, or other persistent identifier associated with the data set(s). If you have 
selected to provide a pre-registered DOI, please be prepared to share the reviewer 
URL associated with your data deposit, upon request by reviewers. 
Where one or multiple data sets are associated with a manuscript, these are not 
formally peer reviewed as a part of the journal submission process. It is the author’s 
responsibility to ensure the soundness of data. Any errors in the data rest solely with 
the producers of the data set(s). 
 
PUBLICATION CHARGES 
There are no submission fees or page charges for this journal. 
Colour figures will be reproduced in colour in your online article free of charge. If it 
is necessary for the figures to be reproduced in colour in the print version, a charge 
will apply. 
Charges for colour figures in print are £300 per figure ($400 US Dollars; $500 
Australian Dollars; €350). For more than 4 colour figures, figures 5 and above will 
be charged at £50 per figure ($75 US Dollars; $100 Australian Dollars; €65). 
Depending on your location, these charges may be subject to local taxes. 
 
COPYRIGHT OPTIONS  
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Copyright allows you to protect your original material, and stop others from using 
your work without your permission. Taylor & Francis offers a number of different 
license and reuse options, including Creative Commons licenses when publishing 
open access. Read more on publishing agreements. 
 
COMPLYING WITH FUNDING AGENCIES 
We will deposit all National Institutes of Health or Wellcome Trust-funded papers 
into PubMedCentral on behalf of authors, meeting the requirements of their 
respective open access policies. If this applies to you, please tell our production 
team when you receive your article proofs, so we can do this for you. Check 
funders’ open access policy mandates here. Find out more about sharing your work. 
 
OPEN ACCESS 
This journal gives authors the option to publish open access via our Open Select 
publishing program, making it free to access online immediately on publication. 
Many funders mandate publishing your research open access; you can check open 
access funder policies and mandates here. 
Taylor & Francis Open Select gives you, your institution or funder the option of 
paying an article publishing charge (APC) to make an article open access. Please 
contact openaccess@tandf.co.uk if you would like to find out more, or go to 
our Author Services website. 
For more information on license options, embargo periods and APCs for this journal 
please go here. 
 
MY AUTHORED WORKS 
On publication, you will be able to view, download and check your article’s metrics 
(downloads, citations and Altmetric data) via My Authored Works on Taylor & 
Francis Online. This is where you can access every article you have published with 
us, as well as your free eprints link, so you can quickly and easily share your work 
with friends and colleagues. 
We are committed to promoting and increasing the visibility of your article. Here are 
some tips and ideas on how you can work with us to promote your research. 
 
ARTICLE REPRINTS 
You will be sent a link to order article reprints via your account in our production 
system. For enquiries about reprints, please contact the Taylor & Francis Author 
Services team at reprints@tandf.co.uk. You can also order print copies of the journal 
issue in which your article appears. 
 
QUERIES 
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Avon and Wiltshire Mental Health Partnership AWP Trust 
AWP Quality Academy 





0117 378 4217 




Evaluating the use of the “My Wellbeing Toolkit’’ 
AWP Reference: E002.2017 Caswell 
 
This letter is to confirm that your evaluation is now approved and also provides you 
with our reference number.   
 
If you do need any further support or information, please contact us using the 
contact details above, quoting our reference number for your study.   
 
The importance of disseminating all evaluation work cannot be over emphasised. It 
is only by sharing our learning that we can improve services across AWP. For this 
reason, the findings of all evaluation work should be reported to the Evaluation 
team via email. The team will champion the results of service evaluations, and work 
with evaluators to ensure those results are disseminated and acted upon, and that 
the results of evaluations are reflected in future service delivery. The team will also 
work with evaluators to produce publications for the public domain. 
 
Furthermore, please remember that this project is service evaluation, not research. 
Therefore, it should not be represented as research in the future through 
publications or other reporting.  
 










Avon and Wiltshire Mental Health Partnership AWP Trust 
AWP Quality Academy 















Evaluating the use of the “My Wellbeing Toolkit’’ 
AWP Reference: 2017.E002 Caswell 
 
This letter is to confirm that your amended evaluation is now approved and also 
provides you with our reference number.   
 
If you do need any further support or information, please contact us using the 
contact details above, quoting our reference number for your study.   
 
The importance of disseminating all evaluation work cannot be over emphasised. It 
is only by sharing our learning that we can improve services across AWP. For this 
reason, the findings of all evaluation work should be reported to the Evaluation 
team via email. The team will champion the results of service evaluations, and work 
with evaluators to ensure those results are disseminated and acted upon, and that 
the results of evaluations are reflected in future service delivery. The team will also 
work with evaluators to produce publications for the public domain. 
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Appendix I: University confirmation of ethical approval 
Dear Amy, 
I am happy to confirm that you now have full ethical approval from the University of 
Bath Psychology Ethics Committee.  
Please use the code 17‐007 for all internal purposes. 
Best of luck with your research, 
Dr. Nathalia Gjersoe 
Chair, Psychology Ethics Committee 
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 Appendix J: Participant Information Sheet 
 
Evaluation of the “My Wellbeing Toolkit” booklet 
Participant Information Sheet 
17 February 2017 
We’d like to invite you to take part in our service evaluation project. Joining the project 
is entirely up to you. Before you decide, we would like you to understand why the 
service evaluation is being done and what it would involve for you. 
The project will evaluate the “My Wellbeing Toolkit” booklet. It will look at whether 
you used the booklet, whether you found it helpful, how it could be improved and 
what made using the booklet difficult. 
The project will involve a short questionnaire about your experiences of the booklet 
and a subset of participants will be invited to participate in a focus group about the 
booklet. You can participate if you are a care coordinator in the recovery team. 
Please read the following information carefully and contact me if there is anything 
that is not clear, or if you would like more information. 
 
Details of the project 
Why are we doing the project? 
The purpose of the project is to evaluate the My Wellbeing Toolkit that is available 
for use in the Recovery Team. 
The project will ask the following questions: 
1. Have care coordinators been using the “My Wellbeing Toolkit” booklet with 
clients? 
2. What have been the barriers and facilitators to using the booklet? 
3. In what ways has using the booklet improved client sessions? 
4. In what ways could the booklet be improved? 
We are doing this service evaluation so that we can improve the booklet for you. The 
evaluation will mean that the booklet is fit for purpose which will make your role 
easier. We want to create guidelines to make using the booklet easier for you and we 
also want to write a second edition of the booklet in the future. By participating in the 
evaluation you will help tell us how the booklet can be used and improved.  
 
What would taking part involve? 
The evaluation has two parts: a questionnaire and a focus group. 
First, a brief, anonymous, questionnaire will ask about your experience of using the 
booklet. The questionnaire will take up to 15 minutes to complete and you will only 
complete it once. You can complete it during working hours, or outside of work. 
After this, a small subset of care coordinators (8-10 people) will be invited to 
participate in the focus group. The focus group includes questions about how often 
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you used the booklet, the barriers and facilitators you have experienced to using the 
booklet, how useful you found it, and what ways you think it could be improved. The 
focus group will last approximately 45 minutes – 1 hour. The focus group will be audio 
recorded. 
You do not need to have used the booklet to participate in either the questionnaire or 
the focus group as we are also interested in the responses of people who haven’t 
used it. 
Who can participate? We are inviting all the care-coordinators in the Recovery 
Team to complete the questionnaire. You can participate even if you have not used 
the booklet.  
Where will the project take place? The project will take place at NHS House. 
 
Who is involved in the service evaluation: 
• Amy Caswell - Trainee Clinical Psychologist, University of Bath – Main 
researcher 
• Dr Emma Griffith - Clinical Psychologist, AWP, and Clinical Tutor at Bath 
University 
• Dr Chris Gillmore – Clinical Psychologist, AWP  
• Dr Hanna van der Woude – Clinical Psychologist, AWP  
The NHS and the University of Bath have reviewed the protocol of this study, and 
have given ethical approval for it. 
 
What are the possible benefits of taking part? 
We are doing this service evaluation so that we can improve the booklet. This will 
mean that any future editions of the booklet are improved.  
Participating in the evaluation will mean that you are taking an active role in shaping 
services. It means you will contribute to guiding the resources you have available to 
you. 
 
What are the possible disadvantages and risks of taking part? 
We have been careful to minimise any possible disadvantages or risks to you. Your 
responses on the questionnaire and focus group will be anonymous, and participation 
is entirely up to you. Please see sections below for further information about this.  
 
Further supporting information  
Do I have to participate? As you have been asked to do this in a professional 
capacity, you may feel pressure to take part in the project or to remain part of it once 
it starts. You are not required to participate, and can choose to withdraw your 
participation at any point during the study. Your decision to participate or not 
participate in the service evaluation will not in any way affect your employment. The 
names of care coordinators who have chosen not to participate will not be made 
available to management. 
 
What will happen if you don’t want to carry on with the project? If you start 
completing the questionnaire and decide you don’t want to continue, you can simply 
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not submit the questionnaire the researcher. Once you have submitted a 
questionnaire to the researcher, this data will be anonymous and you will no longer 
be able to withdraw your responses. 
If you start completing the focus group and decide you don’t want to continue you 
can leave the group and withdraw your responses. You will have 2 weeks after the 
focus group to withdraw your responses should you change your mind about 
participating. After 2 weeks you will no longer be able to withdraw as your responses 
will have been transcribed anonymously. 
 
Are my responses anonymous and confidential? Consent forms and 
questionnaires will be stored separately in a locked filing cabinet. Managers will not 
receive feedback about your responses and will not be told as to whether you used 
the booklet or not.  
Please be assured that questionnaire data is anonymous. You will not write your 
name anywhere on your questionnaire.  
The focus group will be audio-recorded. Your responses during the focus group will 
also be anonymised. Two weeks after the completion of the focus group, the 
recording will be transcribed. At this point, names and identifying information will be 
removed from the transcript. After this, the original audio recording will be destroyed. 
 
What will happen to the responses I give? The responses you give will be collated 
with those submitted by other care-coordinators.  
The raw data will be initially analysed by me. The final analysis will be conducted by 
me in consultation with the other researchers involved in the study, and will not 
include the names of any participants. 
 
What will happen to the findings from the evaluation project? The results of the 
evaluation will be sent to all care coordinators who participated in the study, as well 
as the Therapies Team and the Recovery Team. Versions of the results will also be 
submitted for publication to journals and presentation at conferences deemed 
appropriate. Please be assured that your name will not be identifiable in any version 
of results submitted for publication or presentation. 
 
What if I have concerns about the project? If you have any concerns about the 
evaluation please contact the researcher, Amy Caswell a.caswell@bath.ac.uk, or the 
primary supervisor Dr Emma Griffith e.j.griffith@bath.ac.uk.  
 
Further questions  
Please contact me if you have any further questions about the service evaluation, or 
would like additional information: a.caswell@bath.ac.uk 
Thank you for your time taken to read this sheet and consider taking part in this 
project. 
Amy Caswell 
Clinical Psychologist in Training, University of Bath  
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Appendix M: Questionnaire 




1) Have you used the “My Well-being” Toolkit in your sessions with 
clients? 
 Yes 
 No (please proceed to question 5) 
 
2) How many clients have you used the “My Well-being Toolkit” with? 
 All of my clients 
 Some of my clients  
Please provide approximate number of clients you have used the booklet with 
_____________________ 
 
3) How frequently do you use the booklet on average with clients? 
 Every session 
 Most sessions 
 About half of the time 
 Occasionally 
 Rarely 
 Just once 
 
4) When you use the booklet, how much of the session do you use it 
for? 
SECTION 1: 
USAGE OF THE BOOKLET 
Thank you for agreeing to complete the questionnaire evaluating the “My Well-
being Toolkit” 
Please answer the following questions as accurately as possible. Your answers 
are anonymous. 
If you have used the booklet with clients, or have read it, please complete all 
sections 





 All of the session 
 Most of the session 
 Some of the session 
 A little of the session 
 
5) When you have not used the booklet with clients, why not? (select 
as many as appropriate) 
 It hasn’t been suitable for a client 
 Client has not wanted to use it  
 I have not felt confident using it 
 I don’t find it useful 





6) When you haven’t used it with clients, have you suggested using it 
to them? (select as many as appropriate) 
 Yes but they have not wanted to 
 Yes but it hasn’t been suitable for the work 
 No 
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1) Overall, have you found the booklet helpful/useful? 









2) Did the booklet help provide structure to sessions? 
 Yes, a lot 
 A little 
 No 






3) Did the booklet help develop a shared understanding with clients? 
 Yes, a lot 
 A little 
SECTION 2: 
USEFULNESS OF THE BOOKLET 









4)  Did the booklet promote discussion around recovery? 
 Yes, a lot 
 A little 
 No 






5) Did the booklet facilitate psychological discussion? 
 Yes, a lot 
 A little 
 No 





6) Did the booklet aid discussion of goals and priorities? 
 Yes, a lot 
 A little 
 No 






7) Would you recommend the booklet to another clinician or care-
coordinator? 
 Yes 
 No  
Any additional comments: 





8) Would you recommend the booklet to a client? 
 Yes 
 No  
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Appendix N: Focus group schedule 
 
  
Focus group schedule 
The focus group will cover four primary areas: (1) evaluating in what ways the booklet was helpful (2) 
evaluating times when the booklet was not used (3) Identifying barriers and facilitators to use (4) 
Identifying areas in which the booklet can be improved.  
Example questions are provided below. These will not be prescriptive, although will be used as prompts 
to keep participants on track if necessary. 
Evaluating how the booklet was helpful: 
1. How much did you use the booklet? 
2. In what ways did you find the wellbeing toolkit helpful? What was good about it? 
Prompt if needed: 
a. Did it help provide structure to sessions? 
b. Did it help develop a shared understanding? 
c. Did it help someone move along their recovery? This might include developing hope, 
relationships, empowerment, discovering meaning. 
d. Did it facilitate psychological discussion? 
e. Did it aid discussion of goals and priorities? 
3. Which sections did you find most helpful? (NB a copy of the booklet will be available to look 
through if needed). 
4. When working with a client, what contributed to you deciding to use the booklet? 
Evaluating times when the booklet was not used: 
5. Were there times when you didn’t use the booklet? 
a. If yes, why not?  
Identifying barriers and facilitators to use: 
6. Was there anything that got in the way of using the booklet? 
a. Is there anything that could be put into place to help with this?  
b. Did the booklet come up in supervision? 
c. Has this felt like a priority? 
d. Does it feel like the organisation is supporting use of materials like this? 
 
7. What made using the booklet easier/what facilitated using the booklet? 
a. Is there anything that could be put into place to help with this? 
Now I want to think about whether we should change the booklet: 
8. In what ways do you think the booklet could be improved? 
Prompt if needed: 
a. Are there any sections that could be changed? 
b. How could it be made easier to implement? 
9. In what ways should we keep the booklet the same? 
Now any final thoughts? 
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Appendix P – Journal guidelines (Psycho-oncology) 
1. SUBMISSION 
Thank you for your interest in Psycho-Oncology. Note that submission implies that the content has 
not been published or submitted for publication elsewhere except as a brief abstract in the 
proceedings of a scientific meeting or symposium. 
Once you have prepared your submission in accordance with the Guidelines, manuscripts 
should be submitted online at https://mc.manuscriptcentral.com/pon 
The submission system will prompt you to use an ORCiD (a unique author identifier) to help 
distinguish your work from that of other researchers. Click here to find out more. 
Click here for more details on how to use ScholarOne. 
For help with submissions, please contact Psycho-Oncology@wiley.com 
We look forward to your submission. 
2. AIMS AND SCOPE 
Psycho-Oncology is concerned with the psychological, social, behavioral, and ethical aspects of 
cancer. This sub-speciality addresses the two major psychological dimensions of cancer: the 
psychological responses of patients to cancer at all stages of the disease, and that of their families and 
caretakers; and the psychological, behavioral and social factors that may influence the disease 
process. Psycho-oncology is an area of multi-disciplinary interest and has boundaries with the major 
specialities in oncology: the clinical disciplines (surgery, medicine, pediatrics, radiotherapy), 
epidemiology, immunology, endocrinology, biology, pathology, bioethics, palliative care, 
rehabilitation medicine, clinical trials research and decision making, as well as psychiatry and 
psychology. 
This international journal is published twelve times a year and will consider contributions to research 
of clinical and theoretical interest. Topics covered are wide-ranging and relate to the psychosocial 
aspects of cancer and AIDS-related tumors, including: epidemiology, quality of life, palliative and 
supportive care, psychiatry, psychology, sociology, social work, nursing and educational issues. 
Special reviews are offered from time to time. Summary proceedings of important national and 
international symposia falling within the aims of the journal are presented. 
Manuscripts should be confined to work relating to cancer and AIDS-related tumors. The criteria for 
publication are originality, high scholarly quality as determined by peer review, interest to a wide 
audience of those concerned with psycho-oncology. 
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS 
Psycho-Oncology publishes a number of different article types including: 
• Original Paper 
Original research papers should contain reports of new research findings that make a significant 
contribution to knowledge. Original papers should not exceed 4,000 words (including no more than 
four figures and/or tables) plus up to 40 references. 
• Reviews 
Reviews should be critical reviews of the literature, including systematic reviews and meta-analyses 
and should not exceed 6,000 words, excluding references. Please complete and upload 
a PRISMA or AMSTAR checklist for systematic reviews. 
• Invited Editorials and Commentaries 
Please approach the Editorial Office (Psycho-Oncology@wiley.com) for details. 
• Clinical Correspondence 
This includes brief commentaries, letters to the editor, feasibility studies, clinical updates, case 
reports and brief research reports. They must include five succinct key points (and no abstract), not 
exceed 1,500 words in total (including no more than two figures/tables). References should be limited 
to ten and are not included in the word count.  
• Obituaries 
• Registered Reports 
Psycho-Oncology is offering authors a new article type designed to increase the transparency and 
reproducibility of hypothesis-driven science, the Registered Report. Registered Reports differ from 
conventional research article as part of the review process is conducted before authors collect and 
analyse data. The cornerstone of the Registered Reports format is that a significant part of the 
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manuscript will be assessed prior to data collection, with the highest quality submissions accepted in 
advance. Please view the full Registered Reports author guidelines here to help prepare your 
submission. 
Qualitative manuscript submissions should usually be based on a minimum of 20 respondents. 
Authors may contact the Editor (maggie.watson@live.co.uk) if they require further details. 
For cross sectional studies, we require authors to adhere to the STROBE reporting standards for 
observational research. Please upload your STROBE checklist alongside your submission. 
4. PREPARING YOUR SUBMISSION 
Manuscripts must be submitted as a Word or rtf file and should be written in English. The manuscript 
should be submitted in separate files: main text file; figures. 
Text file 
The text file should be presented in the following order: 
(i) Title; (ii) a short running title of less than 70 characters; (iii) the full names of the authors; (iv) the 
author's institutional affiliations at which the work was carried out, (footnote for author’s present 
address if different to where the work was carried out); (v) abstract; (vi) main text, (vii) 
acknowledgements, (viii) conflict of interest statement, (ix) references, (x) tables (each table 
complete with title and footnotes) (xi) figure legends, (xii) appendices (if relevant). Figures and 
supporting information should be supplied as separate files. 
Title 
The title should be a short informative title that contains the major key words. The title should not 
contain abbreviations (see Wiley's best practice SEO tips) 
Authorship 
Please refer to the journal’s authorship policy the Editorial Policies and Ethical Considerations 
section for details on eligibility for author listing. 
Acknowledgements 
Contributions from anyone who does not meet the criteria for authorship should be listed, with 
permission from the contributor, in an Acknowledgments section. Financial and material support 
should also be mentioned. Thanks to anonymous reviewers are not appropriate. 
Conflict of Interest Statement 
You will be asked to disclose conflicts of interest during the submission process. See the section 
‘Conflict of Interest’ in the Editorial Policies and Ethical Considerations section for details on what to 
include in this section. Please ensure that you liaise with all co-authors to confirm agreement with the 
final statement. The Conflict of Interest statement should be included within the main text file of your 
submission. 
Abstract 
Please provide an abstract of no more than 250 words. Abstracts should be structured according to the 
following headings: objective, methods, results, conclusions. 
Keywords 
Please provide up to 10 keywords and list them in alphabetical order. Please ensure that the 
keywords, cancer and oncology, are used for indexing purposes. Keywords should be taken from 
those recommended by the US National Library of Medicine's Medical Subject Headings (MeSH) 
browser list at https://www.nlm.nih.gov/mesh/. 
Main text 
Where possible, the text should be divided into the following sections: Background, Methods 
(including statistical methods), Results and Conclusions. All papers must include within the 
Conclusions section a paragraph explaining the study limitations (with subtitle “study limitations") 
and a paragraph explaining the clinical implications of the study (with subtitle “clinical 
implications"). 
A statement explicitly describing the ethical background to this study and any institutional or national 
ethical committee approval (including approval number) must be included within the manuscript. 
For clinical trial reports, the clinical trial registration number must be included within the manuscript. 
References 
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All references should be numbered consecutively in order of appearance and should be as complete 
as possible. In text citations should be superscript numbers. Journal titles are abbreviated; 
abbreviations may be found in the following: MEDLINE, Index Medicus, or CalTech Library. 
Submissions are not required to reflect the precise reference formatting of the journal (use of italics, 
bold etc.), however it is important that all key elements of each reference are included. Please see 
below for examples of reference content requirements. 
For more information, please see the Vancouver Reference Style Guide 
Sample references follow: 
Journal Article 
1. Wood WG, Eckert GP, Igbavboa U, Muller WE. Statins and neuroprotection: a prescription to 
move the field forward. Ann N Y Acad Sci 2010; 1199:69-76. 
Book 
2. Hoppert, M. Microscopic techniques in biotechnology. Weinheim: Wiley-VCH; 2003. 
Electronic Material 
3. Cancer-Pain.org [homepage on the internet]. New York: Association of Cancer Online Resources, 
Inc.; c2000–01 [Cited 2015 May 11]. Available from: http://www.cancer-pain.org/. 
Tables 
Tables should be self-contained and complement, but not duplicate, information contained in the text. 
They should be supplied as editable files, not pasted as images. Legends should be concise but 
comprehensive – the table, legend and footnotes must be understandable without reference to the text. 
All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that 
order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should 
be identified in the headings. 
Figure Legends 
Legends should be concise but comprehensive – the figure and its legend must be understandable 
without reference to the text. Include definitions of any symbols used and define/explain all 
abbreviations and units of measurement. 
Preparing Figures 
Although we encourage authors to send us the highest-quality figures possible, for peer-review 
purposes we are happy to accept a wide variety of formats, sizes, and resolutions. 
Click here for the basic figure requirements for figures submitted with manuscripts for initial peer 
review, as well as the more detailed post-acceptance figure requirements. 
Guidelines for Cover Submissions 
If you would like to send suggestions for artwork related to your manuscript to be considered to 
appear on the cover of the journal, please follow these general guidelines. 
Appendices 
Appendices will be published after the references. For submission they should be supplied as separate 
files but referred to in the text. Supporting Information 
Supporting Information 
Supporting information is information that is not essential to the article but that provides greater 
depth and background. It is hosted online, and appears without editing or typesetting. It may include 
tables, figures, videos, datasets, etc. Click here for Wiley’s FAQs on supporting information. 
Note, if data, scripts or other artefacts used to generate the analyses presented in the paper are 
available via a publicly available data repository, authors should include a reference to the location of 
the material within their paper. 
General Style Points 
The following links provide general advice on formatting and style. 
• Abbreviations: In general, terms should not be abbreviated unless they are used repeatedly and the 
abbreviation is helpful to the reader. Initially use the word in full, followed by the abbreviation in 
parentheses. Thereafter use the abbreviation only. 
• Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau 
International des Poids et Mesures (BIPM) website at http://www.bipm.fr for more information about 
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SI units. 
• Trade Names: Chemical substances should be referred to by the generic name only. Trade names 
should not be used. Drugs should be referred to by their generic names. If proprietary drugs have 
been used in the study, refer to these by their generic name, mentioning the proprietary name, and the 
name and location of the manufacturer, in parentheses. 
Wiley Author Resources 
Wiley has a range of resources for authors preparing manuscripts for submission available here. In 
particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search 
Engine Optimization. 
Editing, Translation and Formatting Support: Wiley Editing Services can greatly improve the 
chances of your manuscript being accepted. Offering expert help in English language editing, 
translation, manuscript formatting and figure preparation, Wiley Editing Services ensures that your 
manuscript is ready for submission. 
5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS 
Editorial Review and Acceptance 
The acceptance criteria for all papers is the quality and originality of the research and its significance 
to our readership. Except where otherwise stated, manuscripts are single-blind peer reviewed. Papers 
will only be sent to review if the Editors determine that the paper meets the appropriate quality and 
relevance requirements. Wiley's policy on confidentiality of the review process is available here. 
Appeal of Decision 
Authors who wish to appeal the decision on their manuscript may do so by emailing the Editor within 
28 days of notification of the decision. In such cases, a letter detailing the reasons for appeal as well 
as a full response to any reviewers' comments, if relevant, should be provided to the Editor. If 
appropriate, the manuscript will be sent to another reviewer who has not previously evaluated the 
manuscript. The reviewers' comments, along with any subsequent editorial communications, will be 
assessed by the Editor. The Editor's decision will be final. 
Manuscript Transfer Programme 
Psycho-Oncology collaborates with Wiley’s open access journal Cancer Medicine, to enable rapid 
publication of good quality research that we are unable to accept for publication in Psycho-Oncology. 
Authors will be offered the option of having the paper, along with any related peer reviews, 
automatically transferred for consideration by the Editor of Cancer Medicine. Authors will not need 
to reformat or rewrite their manuscript at this stage, and publication decisions will be made a short 
time after the transfer takes place. The Editor of Cancer Medicine will accept submissions that report 
well-conducted research which reaches the standard acceptable for publication. Cancer Medicine is a 
Wiley Open Access journal and article publication fees apply. For further information, see the cancer 
medicine website. 
Data Sharing and Accessibility 
The journal encourages authors to share the data and other artefacts supporting the results in the 
paper by archiving it in an appropriate public repository. Authors should include a data accessibility 
statement, including a link to the repository they have used, in order that this statement can be 
published alongside their paper. 
Ethics 
A statement explicitly describing the ethical background to this study and any institutional or national 
ethical committee approval must be included within the manuscript. 
Human Studies and Subjects 
For manuscripts reporting medical studies involving human participants, we require a statement 
identifying the ethics committee that approved the study, and that the study conforms to recognized 
standards, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human 
Subjects; or European Medicines Agency Guidelines for Good Clinical Practice. 
Images and information from individual participants will only be published where the authors have 
obtained the individual's prior written informed consent. Authors should note in their methods section 
that informed written consent was obtained. Authors do not need to provide a copy of the consent 
form to the publisher during submission. However, in signing the author license to publish, authors 
are required to confirm that consent has been obtained. The Journal reserves the right to request proof 
of written consent at any time. Wiley has a standard patient consent form available. 
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Clinical Trial Registration 
We require that clinical trials are prospectively registered in a publicly accessible database and 
clinical trial registration numbers should be included in all papers that report their results. Please 
include the name of the trial register and your clinical trial registration number at the end of your 
abstract. If your trial is not registered, or was registered retrospectively, please explain the reasons for 
this. 
Research Reporting Guidelines 
Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. 








• STARD and TRIPOD 
• CHEERS 
• the EQUATOR Network 
• Future of Research Communications and e-Scholarship (FORCE11) 
• ARRIVE guidelines • National Research Council's Institute for Laboratory Animal Research 
guidelines: the Gold Standard Publication Checklist from Hooijmans and colleagues 
• Minimum Information Guidelines from Diverse Bioscience Communities (MIBBI) website; 
Biosharing website 
• REFLECT statement 
Genetic Nomenclature 
Sequence variants should be described in the text and tables using both DNA and protein 
designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS 
guidelines; see http://varnomen.hgvs.org/, where examples of acceptable nomenclature are provided. 
Conflict of Interest 
Psycho-Oncology requires that all authors disclose any potential sources of conflict of interest. Any 
interest or relationship, financial or otherwise that might be perceived as influencing an author's 
objectivity is considered a potential source of conflict of interest. These must be disclosed when 
directly relevant or directly related to the work that the authors describe in their manuscript. Potential 
sources of conflict of interest include, but are not limited to, patent or stock ownership, membership 
of a company board of directors, membership of an advisory board or committee for a company, and 
consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest 
does not preclude publication. If the authors have no conflict of interest to declare, they must also 
state this at submission. It is the responsibility of the corresponding author to review this policy with 
all authors and collectively to disclose with the submission ALL pertinent commercial and other 
relationships. The Conflict of Interest statement should be included within the main text file of your 
submission. 
Funding 
Authors should list all funding sources in the Acknowledgments section. Authors are responsible for 
the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the 
correct nomenclature: http://www.crossref.org/fundingdata/registry.html 
Authorship 
The list of authors should accurately illustrate who contributed to the work and how. All those listed 
as authors should qualify for authorship according to the following criteria: 
1) Have made substantial contributions to conception and design, or acquisition of data, or analysis 
and interpretation of data; 
2) Been involved in drafting the manuscript or revising it critically for important intellectual content; 
3) Given final approval of the version to be published. Each author should have participated 
sufficiently in the work to take public responsibility for appropriate portions of the content; and 
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4) Agreed to be accountable for all aspects of the work in ensuring that questions related to the 
accuracy or integrity of any part of the work are appropriately investigated and resolved. 
Contributions from anyone who does not meet the criteria for authorship should be listed, with 
permission from the contributor, in an Acknowledgments section (for example, to recognize 
contributions from people who provided technical help, collation of data, writing assistance, 
acquisition of funding, or a department chairperson who provided general support). Prior to 
submitting the article all authors should agree on the order in which their names will be listed in the 
manuscript. 
Additional authorship options 
Joint first or senior authorship: In the case of joint first authorship a footnote should be added to the 
author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered 
joint senior author.’ 
ORCID 
As part of our commitment to supporting authors at every step of the publishing process, Psycho-
Oncology requires the submitting author (only) to provide an ORCID iD when submitting a 
manuscript. This takes around 2 minutes to complete. Find more information here. 
Publication Ethics 
Psycho-Oncology is a member of the Committee on Publication Ethics (COPE). Note this journal 
uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in 
submitted manuscripts. Read our Top 10 Publishing Ethics Tips for Authors here. Wiley’s 
Publication Ethics Guidelines can be found at https://authorservices.wiley.com/ethics-
guidelines/index.html 
6. AUTHOR LICENSING 
If your paper is accepted, the author identified as the formal corresponding author will receive an 
email prompting them to log in to Author Services, where via the Wiley Author Licensing Service 
(WALS) they will be required to complete a copyright license agreement on behalf of all authors of 
the paper. 
Authors may choose to publish under the terms of the journal’s standard copyright agreement, 
or OnlineOpen under the terms of a Creative Commons License. 
General information regarding licensing and copyright is available here. To review the Creative 
Commons License options offered under OnlineOpen, please click here. (Note that certain funders 
mandate that a particular type of CC license has to be used; to check this please click here.) 
Self-Archiving definitions and policies. Note that the journal’s standard copyright agreement allows 
for self-archiving of different versions of the article under specific conditions. Please click here for 
more detailed information about self-archiving definitions and policies. 
Open Access fees: If you choose to publish using OnlineOpen you will be charged a fee. A list of 
Article Publication Charges for Wiley journals is available here. 
Funder Open Access: Please click here for more information on Wiley’s compliance with specific 
Funder Open Access Policies. 
7. PUBLICATION PROCESS AFTER ACCEPTANCE 
Accepted article received in production 
When your accepted article is received by Wiley’s production production team, you (corresponding 
authors) will receive an email asking you to login or register with Author Services. You will be asked 
to sign a publication licence at this point. 
Accepted Articles 
The journal offers Wiley’s Accepted Articles service for all manuscripts. This service ensures that 
accepted ‘in press’ manuscripts are published online very soon after acceptance, prior to copy-editing 
or typesetting. Accepted Articles are published online a few days after final acceptance, appear in 
PDF format only, are given a Digital Object Identifier (DOI), which allows them to be cited and 
tracked, and are indexed by PubMed. After publication of the final version article (the article of 
record), the DOI remains valid and can continue to be used to cite and access the article. 
Accepted Articles will be indexed by PubMed; submitting authors should therefore carefully check 
the names and affiliations of all authors provided in the cover page of the manuscript so it is correct 
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for indexing. Subsequently the final copyedited and proofed articles will appear in an issue on Wiley 
Online Library; the link to the article in PubMed will automatically be updated. 
Proofs 
Once your paper is typeset you will receive email notification of the URL from where to download a 
PDF typeset page proof, associated forms and full instructions on how to correct and return the file. 
Please note that you are responsible for all statements made in your work, including changes made 
during the editorial process and thus you must check your proofs carefully. Note that proofs should 
be returned 48 hours from receipt of first proof. 
Early View 
The journal offers rapid speed to publication via Wiley’s Early View service. Early View (Online 
Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note 
there may be a delay after corrections are received before your article appears online, as Editors also 
need to review proofs. Once your article is published on Early View no further changes to your 
article are possible. Your Early View article is fully citable and carries an online publication date and 
DOI for citations. 
8. POST PUBLICATION 
Access and sharing 
When your article is published online: 
• You receive an email alert (if requested). 
• You can share your published article through social media. 
• As the author, you retain free access (after accepting the Terms & Conditions of use, you can view 
your article). 
• The corresponding author and co-authors can nominate up to ten colleagues to receive a publication 
alert and free online access to your article. 
Now is the time to start promoting your article. Find out how to do that here. 
Measuring the impact of your work 
Wiley also helps you measure the impact of your research through our specialist partnerships 
with Kudos and Altmetric. 
9. EDITORIAL OFFICE CONTACT DETAILS 
Psycho-Oncology@wiley.com 
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Appendix T – Participant Information Sheet 
 Participant Information Sheet (V2.1) 
Research study: Psychological experiences of women with cervical cancer 
5th May 2017 
 
We would like to invite you to take part in our research into the psychological experiences of 
women with cervical cancer.  
The study is anonymous and is completed online whenever is convenient for you. It will last 
about 20-30 minutes. You can participate in the study if you are a women, over the age of 25, 
with a current or past diagnosis of cervical cancer. As a small way of saying thank you for 
completing the study, we will make a donation to a charity supporting women’s health on 
your behalf. 
Joining the study is entirely up to you. Before you decide if you want to participate, we would 
like you to understand why the research is being done and what it would involve for you. 
Please read the following information carefully. 
 
About the study 
Greater attention is now being paid to the psychological experiences of women with cervical 
cancer. The charity The Eve Appeal highlighted that there is still a lot we don’t know about 
how cervical cancer affects women psychologically, meaning we don’t always know how best 
to support women. 
Women with cervical cancer can experience a lot of different emotions. We are interested in 
what might lead to difficult emotions and what could reduce difficult emotions. We hope the 
research will help us to improve the experience of women with cervical cancer. 
 
What would taking part involve? 
In the study, we will ask you some questions about yourself, your diagnosis and your 
psychological wellbeing. We will then show you some information about cervical cancer, 
before asking you to complete further questions. 
The study will last 20-30 minutes. It is anonymous, and your name won’t be linked to your 
answers. The study is completed online, so you won’t need to meet a researcher or attend any 
sessions. You can do it at a time convenient for you. 
The study is separate from your standard care from your medical team. Choosing to participate 
will not affect your care in any way, and participation is entirely voluntary. 
 
Who is involved in the study? 
The study is being run through the University of Bath. The researchers involved in the project 
are: 
• Dr  Amy Caswell - Clinical Psychologist in Training, University of Bath – Main 
researcher 
• Dr Cara Davis - Clinical Psychologist and Clinical Tutor at Bath University – 
Project Supervisor 
• Dr Megan Wilkinson-Tough - Clinical Psychologist and Clinical Tutor at Bath 
University – Project Supervisor 
• Dr Sam Cole - Clinical Psychologist, University Hospitals Bristol NHS 
Foundation Trust – Project Supervisor 
The study has been approved by the NHS, Wales REC 3 and the University of Bath, who have 
given ethical approval for it. 
 
Why is this research important? 
We want to ensure that women with cervical cancer receive the best possible psychological 
care and support through their illness, and ensure that any distress is reduced. We don’t feel 
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that enough is being done to understand the experiences of women with cervical cancer, and 
want to start making changes to this. 
We hope that this research will inform psychological support for women with cervical cancer. 
By completing the study you are helping us get one step closer to this goal. 
 
What are the possible benefits of taking part? 
We cannot promise you any direct benefits from participating but taking part will help the 
support provided to those with cervical cancer.  
By choosing to take part in the study you are helping us understand the experiences of women 
with cervical cancer - the more we know, the more we can do to support women in similar 
situations to yourself.  
To say thank you for participating we will also make a £1 charity donation on your behalf. 
The donation will go to charities supporting women with cervical cancer.  
 
What are the possible disadvantages and risks of taking part? 
Your wellbeing is very important to us, and we have been careful to make sure there are no 
disadvantages to you. 
However, as part of the study we will ask you questions that you might find sensitive, 
including questions about your diagnosis and your mental health. We will also give you 
information about cervical cancer. We do recognise that answering questions about your 
illness could bring up some distressing emotions for some women.  
If you find yourself feeling upset or distressed you can stop the study at any time without 
penalty. If you want to stop please press the button saying “exit the study”. 
If you experience any severe distress and feel you need support, please contact your lead 
clinical nurse or GP. Further sources of support include: 
• Jo’s Cervical Cancer Trust (www.jostrust.org.uk).  
• The Samaritans (phone 116 123) 
You can also contact the lead investigator for the study, Dr Amy Caswell, at 
a.caswell@bath.ac.uk or by phoning . If you have a query about the study and 
do not want to contact the lead investigator directly, please Dr Cara Davis, 
c.davis@bath.ac.uk, or Dr Megan Wilkinson-Tough, m.wilkinson-tough@bath.ac.uk. 
 
Further information: 
How do we keep your information confidential? Your answers to the questionnaire will be 
completely anonymous. You will not be asked to give your name or email address. This means 
your name will not be linked to any answers you give, and will not be included in any write 
ups of the study. 
What happens if I change my mind about participating? You can change your mind about 
participating in the survey at any point before submitting your answers, with no negative 
consequences. If you want to leave the study please press the button saying “exit the study”. 
At the end of the study you will confirm that you are happy for your answers to be submitted 
to the researchers. After you have submitted your answers we cannot withdraw this 
information because it will have been submitted anonymously and we will not be able to 
identify that it was yours. 
What will you do with the results of the study? The results from the study will be written 
up and submitted as part of a postgraduate academic study programme, and might be 
submitted for publication in a journal. The results might also be sent to charities and other 
services supporting women with cervical cancer, so that they can show to results on their 
website or in their services. The results will be aggregated and your name or any identifying 
information will not be written in any write-up.  
If you would like to know the aggregate results of the study then please email the main 
researcher, a.caswell@bath.ac.uk, and you will be sent them when available. The contact 
details you provide will not be linked with your research responses in any way and will be 
stored securely. Please note we will not be able to send you your individual results, only the 
aggregated results. 
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The anonymous data will be kept on file in accordance with UK data laws. The anonymised 
data will be stored, and might be distributed to other research institutes for research purposes 
should they request it. Your name will not be distributed at any point. 
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Appendix U – Consent process (completed in Qualtrics) 
 





Appendix V – Brief procedure 
 
Below is a list of the measures that will be completed in the study. All measures are 
include below. 
As the study will be completed online using the survey software Qualtrics, all 
measures will be uploaded to Qualtrics and formatted according to its software. 
Please see IRAS checklist documents for questionnaires as uploaded to Qualtrics. 
 
The following measures will be completed in the following order: 
1. Baseline questionnaires: 
a. Demographic questionnaire 
b. Measure of lifetime depression and anxiety 
c. Hospital anxiety and depression scale (HADS; validated 
questionnaire) 
d. Warwick-Edinburgh Mental Wellbeing Scale (WEMWS; validated 
questionnaire) 
e. State Shame and Guilt Scale (SSGS; validated questionnaire) & 
Adapted State Shame and Guilt Scale (aSSGS) combined. 
2. Multiple choice quiz 
3. Information provision procedure* 
4. Post information questionnaires* 
a. SSGS (validated questionnaire) & aSSGS 
b. Brief mood ratings 
c. Measures of intended behaviour 
5. Brief version of multiple choice quiz (knowledge check) 
*There are three levels of information. Participants will complete the post information 
questionnaires after each level of information. 
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Appendix W – Baseline questionnaires 
Note – copyrighted questionnaires have not been included. 
Demographic information 
 
General Demographic information: 
 
1. How old are you? (space to respond) 
 
2. What is your highest level of education? 
a. Less than GCSE 
b. GCSE (or equivalent) 
c. A-levels (or equivalent) 
d.  Undergraduate degree 
e. Postgraduate degree 
f. Prefer not to answer 
 
3. Where do you currently live? 
a. UK 
b. USA 
c. Other (please provide details) 
d. Prefer not to answer 
 
4. What is your ethnic group? Choose one option that best describes your ethnic 
group or background 
a. White 
b. Mixed/multiple ethnic groups 
c. Asian/Asian British 
d. Black/ African/ Caribbean/ Black British 
e. Other ethnic group 
f. Prefer not to answer 
 
5. How would you describe your current relationship status? Please choose one 
option that best describes your current relationship status. 
a. Single 
b. In (a) non-exclusive or casual relationship(s) 
c. In a committed/exclusive relationship 
d. Married or domestic partnership 
e. Widowed 
f. Divorced or separated 
g. Other (please provide details) 
h. Prefer not to answer 
 
6. How did you find out about this study 
a. Online 
b. Word of mouth 
c. Bristol NHS Trust 
d. London NHS Trust 
e. Other NHS trust 
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f. Prefer not to answer 
g. Other (please provide details) 
 
Cancer demographic information: 
 
The following questions ask details about your cancer diagnosis. Lots of women 
don’t know this level of detail – this is absolutely normal, and you should simply 
choose “I don’t know”, or the answer that best fits. 
 
7. What type of cervical cancer have you been/were you diagnosed with? 
a. Squamous cell cancer 
b. Adenocarcinoma 
c. Other (please provide details) 
d. I don’t know 
 




d. 4  
e. I’m in remission  
f. I don’t know 
 
9. What treatment have you had for cervical cancer? Please tick as many as are 
relevant – if you know the specific type of therapy please tick the appropriate 
box, otherwise tick the general type of treatment 
a. Surgery (I don’t know specific details) 
i. Conization/cone biopsy 
ii. Hysterectomy 
iii. Radical trachelectomy 
iv. Bilateral salpingo-oophorectomy 
v. Pelvic exenteration 
b. Radiation therapy 
i. External radiation therapy 
ii. Internal radiation therapy 
c. Chemotherapy 
d. Targeted (biological) therapies 
 
10. When were you diagnosed with cervical cancer? 
a. Less than 1 month ago 
b. Between 1 and 6 months ago 
c. Between 6 months and a year ago 
d. Between a year and 2 years ago 
e. Between 2 and 5 years ago 
f. More than 5 years ago 
 
 
Knowledge of cervical cancer, general information  
 
11. How would you rate your knowledge of cervical cancer? 
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1 (I have no knowledge) – 10 (I am very knowledgeable) 
 
Lifetime depression and anxiety: 
 
12. Have you ever had a period of time during your life when you were feeling 
depressed or down most of the day nearly every day? 
a. Yes, once 
b. Yes, more than once 
c. No 
 
13. Have you ever had a period of time during your life when you were feeling 
very anxious or worried most of the day nearly every day? 
a. Yes, once 
b. Yes, more than once 
c. No 
 
Support from mental health services: 
 
14. Since being diagnosed with cervical cancer have you received support for 
mental health needs from your GP, mental health services or voluntary 
organisations? 
a. Yes (please provide any details you can remember) 
b. No 
 
Adapted State Shame and Guilt Scale  
 
Adapted from the state shame and guilt scale. 
 
The following are some statements that may or may not describe how you are 
feeling RIGHT NOW. Please rate each statement using the 5 point scale below. 




I think other people feel good about me 1-------------2-------------3-------------4--------------5 
I think other people want me to sink into the floor and 
disappear 
1-------------2-------------3-------------4--------------5 
I think other people feel remorse, regret about something 
I have done 
1-------------2-------------3-------------4--------------5 
I think other people see me as worthwhile, valuable 1-------------2-------------3-------------4--------------5 
I think other people see me as small 1-------------2-------------3-------------4--------------5 
I think other people feel tension about something I have 
done 
1-------------2-------------3-------------4--------------5 
I think other people see me as capable, useful 1-------------2-------------3-------------4--------------5 
I think other people see me as a bad person 1-------------2-------------3-------------4--------------5 
I think other people cannot stop thinking about 
something bad I have done 
1-------------2-------------3-------------4--------------5 
I think other people feel proud of me 1-------------2-------------3-------------4--------------5 
I think other people see me as humiliated, disgraced 1-------------2-------------3-------------4--------------5 
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I think other people think I should apologise, confess 1-------------2-------------3-------------4--------------5 
I think other people feel pleased about something I have 
done 
1-------------2-------------3-------------4--------------5 
I think other people see me as worthless, powerless  
I think other people feel bad about something I have 
done 
1-------------2-------------3-------------4--------------5 
Multiple Choice Quiz 
 
Please answer the following questions about cervical cancer. Please select one 
answer per question.  
1. Where is the cervix located in the body? 
a. In the ovaries 
b. The lower, narrower part of the uterus 
c. In the stomach 
d. In the feet 
2. Cervical cancer is cancer of the… 
a. Breast 
b. Cervix or neck of the womb 
c. Brain 
d. Blood 
3. How many women with cervical cancer are under the age of 50? 
a. Less than 10% 
b. Less than 50% 
c. More than 50% 
d. More than 90% 
4. Cervical cancer is mainly associated with… * 
a. Infection with human papillomavirus (HPV) 
b. Smoking 
c. Infection with hepatitis 
d. Drinking alcohol 
5. 5. What are the symptoms of cervical cancer in the early stages? 
a. Typically, there are no obvious symptoms  
b. Abdominal cramps  
c. Nausea  
d. Anaemia 
6. Human papillomavirus (HPV) is spread by… * 
a. Coughing and sneezing 
b. Not washing your clothes properly 
c. Intimate contact with infected people, especially through sex 
d. Contact with contaminated surfaces 
7. HPV can cause… 
a. A cough 
b. Changes in cervical cells 
c. Changes in iron levels in the blood 
d. Changes in hormones 
8. Approximately how many people will get HPV at some point in their 
lifetime? * 
 
*these questions will be used to establish the baseline knowledge of participants  
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Appendix X – Information Provision Procedure 
Note - Three levels of information about HPV will be presented to participants. 
Participants will see one level of information at a time. They will click through to the 
next page once they have read the information. The three levels of information are: 
Information level 1: Both conditions will first receive general information 
about HPV.  
Information level 2: Condition A will receive information on the high 
prevalence of HPV. Condition B will receive information that HPV is sexually 
transmitted.  
Information level 3: Condition A will receive information that will receive 
information that HPV is sexually transmitted. Condition B will receive 
information on the high prevalence of HPV. 
 
First participants will see an instruction page with the following text: 
 
For the next part of the study you will be shown some information about cervical 
cancer. You will then be asked questions about how you feel about that information. 
You will see three pieces of information, and will answer questions after each. 
Please read each piece of information carefully before answering the questions 
about it. 
 
On the second page they will see the relevant information about HPV, depending on 
the level of information. Information will be preceded by the statement: 
 
Please take a minute to read the following information: 
 
General information: 
“A virus called human papillomavirus (HPV) is now known to be involved 
in the development of cervical cancer (cancer of the cervix or neck of the 
womb).  
For most women, the immune system clears the virus and there are no health 
problems associated with it.  
However, if infection persists, it can lead to abnormalities in the cells of the 
cervix.  
These cells then have an increased risk of becoming cancerous.” 
 
Information that HPV is sexually transmitted: 
“HPV is transmitted through intimate skin-to-skin contact during sex. It is 
described as being sexually-transmitted.” 
 
Information on the high prevalence of HPV: 
“Many people are surprised to discover just how common HPV is. Currently, 
around 80% of people will be infected with HPV at some point in their lives. 





Appendix Y – Post-information questionnaires 
Note – all post-information questionnaires will be prefaced with the statement “take 
a minute to think about the information that you just read [about HPV and cervical 
cancer/that HPV is sexually transmitted/that HPV is very common, with around 80% 
of people being infected with it during their lifetime (deleted as appropriate)]” 
 
State Shame and Guilt Scale 
Same as in baseline measures. 
 
Adapted State Shame and Guilt Scale 
Same as in baseline measures. 
 
Brief mood ratings 
When you think about the information you just read [about HPV/about HPV being 
very common/about HPV being sexually transmitted)… 
1. How would you rate your mood? 0=very low in mood, 10= very high in 
mood 
2. How would you rate your wellbeing? 0=very poor wellbeing, 10 = very good 
wellbeing 




      157 
Appendix Z – Debrief materials 
Thank you for taking the time to participate in our study, we appreciate it. To thank 
you for participating, we will donate £1 to a charity supporting women with cervical 
cancer. Thanks to your participation our donation is growing! 
Background to the study 
The study was an investigation into the experiences of women with cervical cancer, 
particularly concerning knowledge and information about HPV. As you were told, 
cervical cancer is caused by Human Papilloma Virus (HPV). HPV is described as a 
sexually transmitted virus, as it is transmitted through skin-to-skin contact during sex. 
The virus is very common, and it is thought that around 80% of people will contract 
it at some point in their lifetime. Most people won’t develop any problems from HPV, 
although it can cause changes in cervical cells, which then have an increased risk of 
becoming cancerous. 
Research has found that cervical cancer patients can experience raised levels of 
depression and anxiety. They can also experience a lot of shame about their diagnosis. 
We wonder whether shame, anxiety and depression might be because of knowledge 
that HPV is sexually transmitted. This has never been researched in women with 
cervical cancer. On the other hand, knowing how common HPV is can reduce any 
feelings of shame, and we wonder whether this could be helpful information for 
cancer patients.  
The study 
In the study, you first answered a number of questions about yourself. You then read 
general information about HPV, before answering the questions about how you felt. 
You then either read information that HPV is sexually transmitted OR that it is very 
common, before answering how you felt. You then read the other information (HPV 
is sexually transmitted OR is very common) before saying how you felt.  
Half the participants read the information that HPV is sexually transmitted first, and 
half read that it is very common first. 
This will allow us to look at how information that HPV is sexually transmitted is 
experienced by women, and whether the information that HPV is very common 
reduces any negative feelings.  
We hope that this research will inform us of how to present this information to women, 
to reduce any distress arising from it. 
If you need further support 
Once again, we thank you for taking the time to do this study. We really appreciate 
the contribution you have made to understanding the experiences of women with 
cervical cancer. 
We hope that participating in this study has been interesting. If you have any questions 
or concerns, please contact Dr Amy Caswell at a.caswell@bath.ac.uk, or either 
supervisor (c.davis@bath.ac.uk; m.wilkinson-tough@bath.ac.uk).  
If the study has made you feel you might benefit from further emotional support, 
please contact your lead clinical nurse or GP. Jo’s cervical cancer trust is also an 
excellent source of support for women with cervical cancer (www.jostrust.org.uk).  
If you feel you need more immediate support or are concerned for your immediate 
wellbeing, please contact the Samaritans by calling them on 116 123 – phone calls are 
free from UK landlines and mobiles. 
 
Finally, we would like to say thank you once again for participating in the study – we 
really appreciate your time and contribution. 
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